{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:14:40Z","timestamp":1790637280929,"version":"4.1.0"},"reference-count":278,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101108"],"award-info":[{"award-number":["82101108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230032"],"award-info":[{"award-number":["82230032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["SBGJ202101011"],"award-info":[{"award-number":["SBGJ202101011"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Behcet\u2019s disease (BD) is a rare but globally distributed vasculitis that primarily affects populations in the Mediterranean and Asian regions. Behcet\u2019s uveitis (BU) is a common manifestation of BD, occurring in over two-thirds of the patients. BU is characterized by bilateral, chronic, recurrent, non-granulomatous uveitis in association with complications such as retinal ischemia and atrophy, optic atrophy, macular ischemia, macular edema, and further neovascular complications (vitreous hemorrhage, neovascular glaucoma). Although the etiology and pathogenesis of BU remain unclear, numerous studies reveal that genetic factors (such as <jats:italic>HLA-B51<\/jats:italic>), dysregulated immune responses of both the innate and adaptive immune systems, infections (such as streptococcus), and environmental factors (such as GDP) are all involved in its development. Innate immunity, including hyperactivity of neutrophils and \u03b3\u03b4T cells and elevated NK1\/NK2 ratios, has been shown to play an essential role in this disease. Adaptive immune system disturbance, including homeostatic perturbations, Th1, Th17 overaction, and Treg cell dysfunction, is thought to be involved in BU pathogenesis. Treatment of BU requires a tailored approach based on the location, severity of inflammation, and systemic manifestations. The therapy aims to achieve rapid inflammation suppression, preservation of vision, and prevention of recurrence. Systemic corticosteroids combined with other immunosuppressive agents have been widely used to treat BU, and beneficial effects are observed in most patients. Recently, biologics have been shown to be effective in treating refractory BU cases. Novel therapeutic targets for treating BU include the LCK gene, Th17\/Treg balance, JAK pathway inhibition, and cytokines such as IL-17 and ROR\u03b3t. This article summarizes the recent studies on BU, especially in terms of pathogenesis, diagnostic criteria and classification, auxiliary examination, and treatment options. A better understanding of the significance of microbiome composition, genetic basis, and persistent immune mechanisms, as well as advancements in identifying new biomarkers and implementing objective quantitative detection of BU, may greatly contribute to improving the adequate management of BU patients.<\/jats:p>","DOI":"10.1186\/s12974-024-03123-6","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:02:37Z","timestamp":1716390157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Decoding Behcet\u2019s Uveitis: an In-depth review of pathogenesis and therapeutic advances"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuxuan","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"issue":"6","key":"3123_CR1","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225.","journal-title":"Ann Rheum Dis"},{"key":"3123_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fimmu.2019.01067","volume":"10","author":"P Leccese","year":"2019","unstructured":"Leccese P, Alpsoy E. Behcet\u2019s Disease: an overview of Etiopathogenesis. Front Immunol. 2019;10:1067. https:\/\/doi.org\/10.3389\/fimmu.2019.01067.","journal-title":"Front Immunol"},{"key":"3123_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4939-8546-3_2","volume":"1802","author":"G Bodis","year":"2018","unstructured":"Bodis G, Toth V, Schwarting A. Role of human leukocyte antigens (HLA) in Autoimmune diseases. Methods Mol Biol. 2018;1802:11\u201329. https:\/\/doi.org\/10.1007\/978-1-4939-8546-3_2.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"3123_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","volume":"51","author":"C Maldini","year":"2012","unstructured":"Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887\u2013900. https:\/\/doi.org\/10.1093\/rheumatology\/ker428.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3123_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/art.41998","volume":"74","author":"G Su","year":"2022","unstructured":"Su G, Zhong Z, Zhou Q, Du L, Ye Z, Li F, et al. Identification of novel risk loci for Behcet\u2019s Disease-Related Uveitis in a Chinese Population in a genome-wide Association study. Arthritis Rheumatol. 2022;74(4):671\u201381. https:\/\/doi.org\/10.1002\/art.41998.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3123_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.clnu.2020.05.049","volume":"40","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Su G, Du L, Zhou Q, Li F, Chi W, et al. Higher 25-hydroxyvitamin D level is associated with increased risk for Behcet\u2019s disease. Clin Nutr. 2021;40(2):518\u201324. https:\/\/doi.org\/10.1016\/j.clnu.2020.05.049.","journal-title":"Clin Nutr"},{"issue":"1","key":"3123_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2017.1279840","volume":"25","author":"ET Cunningham Jr","year":"2017","unstructured":"Cunningham ET Jr., Tugal-Tutkun I, Khairallah M, Okada AA, Bodaghi B, Zierhut M. Behcet Uveitis. Ocul Immunol Inflamm. 2017;25(1):2\u20136. https:\/\/doi.org\/10.1080\/09273948.2017.1279840.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"3123_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ophtha.2007.04.056","volume":"115","author":"P Yang","year":"2008","unstructured":"Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of Chinese patients with Behcet\u2019s disease. Ophthalmology. 2008;115(2):312. https:\/\/doi.org\/10.1016\/j.ophtha.2007.04.056. 8 e4.","journal-title":"Ophthalmology"},{"issue":"1","key":"3123_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bjophthalmol-2020-315960","volume":"105","author":"P Yang","year":"2021","unstructured":"Yang P, Zhong Z, Du L, Li F, Chen Z, Zhu Y, et al. Prevalence and clinical features of systemic diseases in Chinese patients with uveitis. Br J Ophthalmol. 2021;105(1):75\u201382. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-315960.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"3123_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bjo.40.6.355","volume":"40","author":"A Feigenbaum","year":"1956","unstructured":"Feigenbaum A. Description of Behcet\u2019s syndrome in the hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40(6):355\u20137. https:\/\/doi.org\/10.1136\/bjo.40.6.355.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"3123_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","volume":"17","author":"A Greco","year":"2018","unstructured":"Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. Behcet\u2019s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567\u201375. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.006.","journal-title":"Autoimmun Rev"},{"issue":"4 Suppl 60","key":"3123_CR12","first-page":"S2","volume":"28","author":"H Behcet","year":"2010","unstructured":"Behcet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S2\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"3123_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-2133.2007.08116.x","volume":"157","author":"E Alpsoy","year":"2007","unstructured":"Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, et al. Clinical features and natural course of Behcet\u2019s disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157(5):901\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08116.x.","journal-title":"Br J Dermatol"},{"issue":"8697","key":"3123_CR14","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Behcet\u2019s disease","year":"1990","unstructured":"Criteria for diagnosis of Behcet\u2019s disease. International Study Group for Behcet\u2019s Disease. Lancet. 1990;335(8697):1078\u201380.","journal-title":"Lancet"},{"issue":"3","key":"3123_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Behcet\u2019s D","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Behcet\u2019s D. The International Criteria for Behcet\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338\u201347. https:\/\/doi.org\/10.1111\/jdv.12107.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3123_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2021.03.058","volume":"228","author":"Standardization of Uveitis Nomenclature Working G","year":"2021","unstructured":"Standardization of Uveitis Nomenclature Working G. Classification criteria for Behcet Disease Uveitis. Am J Ophthalmol. 2021;228:80\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2021.03.058.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"3123_CR17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1080\/09273948.2020.1736310","volume":"29","author":"I Tugal-Tutkun","year":"2021","unstructured":"Tugal-Tutkun I, Onal S, Stanford M, Akman M, Twisk JWR, Boers M, et al. An algorithm for the diagnosis of Behcet Disease Uveitis in adults. Ocul Immunol Inflamm. 2021;29(6):1154\u201363. https:\/\/doi.org\/10.1080\/09273948.2020.1736310.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"3123_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/25785826.2020.1800244","volume":"44","author":"H Keino","year":"2021","unstructured":"Keino H. Evaluation of disease activity in uveoretinitis associated with Behcet\u2019s disease. Immunol Med. 2021;44(2):86\u201397. https:\/\/doi.org\/10.1080\/25785826.2020.1800244.","journal-title":"Immunol Med"},{"issue":"3","key":"3123_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"Jabs DA","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509\u201316. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"3123_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467\u201371. https:\/\/doi.org\/10.1016\/s0161-6420(85)34001-0.","journal-title":"Ophthalmology"},{"issue":"17","key":"3123_CR21","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Behcet\u2019s disease. N Engl J Med. 1999;341(17):1284\u201391. https:\/\/doi.org\/10.1056\/NEJM199910213411707.","journal-title":"N Engl J Med"},{"issue":"10","key":"3123_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1046\/j.1365-4362.2003.01893.x","volume":"42","author":"G Azizlerli","year":"2003","unstructured":"Azizlerli G, Kose AA, Sarica R, Gul A, Tutkun IT, Kulac M, et al. Prevalence of Behcet\u2019s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803\u20136. https:\/\/doi.org\/10.1046\/j.1365-4362.2003.01893.x.","journal-title":"Int J Dermatol"},{"issue":"6","key":"3123_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3349\/ymj.1997.38.6.411","volume":"38","author":"CC Zouboulis","year":"1997","unstructured":"Zouboulis CC, Kotter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, et al. Epidemiological features of adamantiades-Behcet\u2019s disease in Germany and in Europe. Yonsei Med J. 1997;38(6):411\u201322. https:\/\/doi.org\/10.3349\/ymj.1997.38.6.411.","journal-title":"Yonsei Med J"},{"issue":"8","key":"3123_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"N Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet\u2019s disease susceptibility loci. Nat Genet. 2010;42(8):703\u20136. https:\/\/doi.org\/10.1038\/ng.624.","journal-title":"Nat Genet"},{"issue":"1","key":"3123_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/09273948.2016.1196714","volume":"26","author":"FN Yalcindag","year":"2018","unstructured":"Yalcindag FN, Ozdal PC, Ozyazgan Y, Batioglu F, Tugal-Tutkun I, Group BS. Demographic and clinical characteristics of Uveitis in Turkey: the First National Registry Report. Ocul Immunol Inflamm. 2018;26(1):17\u201326. https:\/\/doi.org\/10.1080\/09273948.2016.1196714.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"3123_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jfo.2020.04.058","volume":"44","author":"D Saadouli","year":"2021","unstructured":"Saadouli D, Lahmar A, Ben Mansour K, El Afrit N, Yahyaoui S, El Afrit MA. [Ocular manifestations of Behcet\u2019s disease]. J Fr Ophtalmol. 2021;44(2):196\u2013202. https:\/\/doi.org\/10.1016\/j.jfo.2020.04.058.","journal-title":"J Fr Ophtalmol"},{"issue":"6","key":"3123_CR27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/14397595.2018.1558752","volume":"29","author":"F Davatchi","year":"2019","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Abdolahi BS, Nadji A, et al. Behcet\u2019s disease in Iran: analysis of 7641 cases. Mod Rheumatol. 2019;29(6):1023\u201330. https:\/\/doi.org\/10.1080\/14397595.2018.1558752.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"3123_CR28","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/09273948.2020.1714060","volume":"29","author":"A Abdelwareth Mohammed","year":"2021","unstructured":"Abdelwareth Mohammed A, Soliman MM, Osman AA, El-Zanaty RT. Patterns of Uveitis in Egypt. Ocul Immunol Inflamm. 2021;29(5):1007\u201316. https:\/\/doi.org\/10.1080\/09273948.2020.1714060.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"3123_CR29","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s10792-021-01791-4","volume":"41","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Kaburaki T, Tanaka R, Shirahama S, Komae K, Nakahara H, et al. Incidence and changing patterns of uveitis in Central Tokyo. Int Ophthalmol. 2021;41(7):2377\u201388. https:\/\/doi.org\/10.1007\/s10792-021-01791-4.","journal-title":"Int Ophthalmol"},{"issue":"6 Suppl 102","key":"3123_CR30","first-page":"82","volume":"34","author":"B Bitik","year":"2016","unstructured":"Bitik B, Tufan A, Sahin K, Sucullu Karadag Y, Can Sandikci S, Mercan R, et al. The association between the parenchymal neurological involvement and posterior uveitis in Behcet\u2019s syndrome. Clin Exp Rheumatol. 2016;34(6 Suppl 102):82\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"3123_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/14397595.2018.1457424","volume":"29","author":"A Suwa","year":"2019","unstructured":"Suwa A, Horita N, Ishido T, Takeuchi M, Kawagoe T, Shibuya E, et al. The ocular involvement did not accompany with the genital ulcer or the gastrointestinal symptoms at the early stage of Behcet\u2019s disease. Mod Rheumatol. 2019;29(2):357\u201362. https:\/\/doi.org\/10.1080\/14397595.2018.1457424.","journal-title":"Mod Rheumatol"},{"key":"3123_CR32","doi-asserted-by":"publisher","first-page":"9518065","DOI":"10.1155\/2018\/9518065","volume":"2018","author":"MA Hussein","year":"2018","unstructured":"Hussein MA, Eissa IM, Dahab AA. Vision-Threatening Behcet\u2019s Disease: severity of ocular involvement predictors. J Ophthalmol. 2018;2018:9518065. https:\/\/doi.org\/10.1155\/2018\/9518065.","journal-title":"J Ophthalmol"},{"issue":"1","key":"3123_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13075-022-02782-1","volume":"24","author":"CC Hou","year":"2022","unstructured":"Hou CC, Luo D, Bao HF, Ye JF, Ma HF, Shen Y, et al. Clinical heterogeneity of ocular Behcet\u2019s syndrome versus intestinal Behcet\u2019s syndrome: a cross-sectional study from Shanghai Behcet\u2019s syndrome database. Arthritis Res Ther. 2022;24(1):98. https:\/\/doi.org\/10.1186\/s13075-022-02782-1.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"3123_CR34","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/02713680500263606","volume":"30","author":"P Yang","year":"2005","unstructured":"Yang P, Zhang Z, Zhou H, Li B, Huang X, Gao Y, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res. 2005;30(11):943\u20138. https:\/\/doi.org\/10.1080\/02713680500263606.","journal-title":"Curr Eye Res"},{"issue":"1","key":"3123_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12969-016-0070-z","volume":"14","author":"I Kone-Paut","year":"2016","unstructured":"Kone-Paut I. Behcet\u2019s disease in children, an overview. Pediatr Rheumatol Online J. 2016;14(1):10. https:\/\/doi.org\/10.1186\/s12969-016-0070-z.","journal-title":"Pediatr Rheumatol Online J"},{"key":"3123_CR36","doi-asserted-by":"publisher","unstructured":"Ostrovsky M, Rosenblatt A, Iriqat S, Shteiwi A, Sharon Y, Kramer M, et al. Ocular Behcet Disease-Clinical manifestations, treatments and outcomes according to Age at Disease Onset. Biomedicines. 2023;11(2). https:\/\/doi.org\/10.3390\/biomedicines11020624.","DOI":"10.3390\/biomedicines11020624"},{"issue":"1","key":"3123_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0002-9394(03)00110-7","volume":"136","author":"PK Rabiah","year":"2003","unstructured":"Rabiah PK, Vitale AT. Noninfectious uveitis and pregnancy. Am J Ophthalmol. 2003;136(1):91\u20138. https:\/\/doi.org\/10.1016\/s0002-9394(03)00110-7.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3123_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2004.03.022.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"3123_CR39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/ard.43.6.783","volume":"43","author":"H Yazici","year":"1984","unstructured":"Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient\u2019s sex on the prevalence and severity of manifestations of Behcet\u2019s syndrome. Ann Rheum Dis. 1984;43(6):783\u20139. https:\/\/doi.org\/10.1136\/ard.43.6.783.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3123_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/gene.2016.28","volume":"17","author":"S Yavuz","year":"2016","unstructured":"Yavuz S, Akdeniz T, Hancer V, Bicakcigil M, Can M, Yanikkaya-Demirel G. Dual effects of testosterone in Behcet\u2019s disease: implications for a role in disease pathogenesis. Genes Immun. 2016;17(6):335\u201341. https:\/\/doi.org\/10.1038\/gene.2016.28.","journal-title":"Genes Immun"},{"issue":"5","key":"3123_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/09273948.2013.795228","volume":"21","author":"I Tugal-Tutkun","year":"2013","unstructured":"Tugal-Tutkun I, Gupta V, Cunningham ET. Differential diagnosis of behcet uveitis. Ocul Immunol Inflamm. 2013;21(5):337\u201350. https:\/\/doi.org\/10.3109\/09273948.2013.795228.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"3123_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/IIO.0b013e318265d56a","volume":"52","author":"I Tugal-Tutkun","year":"2012","unstructured":"Tugal-Tutkun I. Imaging in the diagnosis and management of Behcet disease. Int Ophthalmol Clin. 2012;52(4):183\u201390. https:\/\/doi.org\/10.1097\/IIO.0b013e318265d56a.","journal-title":"Int Ophthalmol Clin"},{"issue":"1","key":"3123_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12348-020-00226-y","volume":"10","author":"I Ksiaa","year":"2020","unstructured":"Ksiaa I, Ben Aoun S, Zina S, Nefzi D, Khochtali S, Khairallah M. Sequential bilateral Behcet\u2019s neuroretinitis associated with prepapillary vitreous exudate: case report. J Ophthalmic Inflamm Infect. 2020;10(1):33. https:\/\/doi.org\/10.1186\/s12348-020-00226-y.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"1","key":"3123_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","volume":"25","author":"I Tugal-Tutkun","year":"2017","unstructured":"Tugal-Tutkun I, Ozdal PC, Oray M, Onal S. Review for Diagnostics of the year: Multimodal Imaging in Behcet Uveitis. Ocul Immunol Inflamm. 2017;25(1):7\u201319. https:\/\/doi.org\/10.1080\/09273948.2016.1205100.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"3123_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/09273948.2019.1685108","volume":"29","author":"M Pei","year":"2021","unstructured":"Pei M, Zhao C, Gao F, Qu Y, Liang A, Xiao J, et al. Analysis of Parafoveal Microvascular Abnormalities in Behcet\u2019s Uveitis using projection-resolved Optical Coherence Tomographic Angiography. Ocul Immunol Inflamm. 2021;29(3):524\u20139. https:\/\/doi.org\/10.1080\/09273948.2019.1685108.","journal-title":"Ocul Immunol Inflamm"},{"key":"3123_CR46","doi-asserted-by":"publisher","unstructured":"Herbort CP Jr., Papasavvas I, Tugal-Tutkun I. Benefits and limitations of OCT-A in the diagnosis and Follow-Up of posterior intraocular inflammation in current clinical practice: a Valuable Tool or a Deceiver? Diagnostics (Basel). 2022;12(10). https:\/\/doi.org\/10.3390\/diagnostics12102384.","DOI":"10.3390\/diagnostics12102384"},{"issue":"1","key":"3123_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/09273940490518757","volume":"13","author":"S Gedik","year":"2005","unstructured":"Gedik S, Akova Y, Yilmaz G, Bozbeyoglu S. Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Behcet\u2019s disease. Ocul Immunol Inflamm. 2005;13(1):51\u20138. https:\/\/doi.org\/10.1080\/09273940490518757.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"3123_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/0974-9233.58425","volume":"16","author":"I Tugal-Tutkun","year":"2009","unstructured":"Tugal-Tutkun I. Behcet\u2019s Uveitis. Middle East Afr J Ophthalmol. 2009;16(4):219\u201324. https:\/\/doi.org\/10.4103\/0974-9233.58425.","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"1","key":"3123_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/09273940802553279","volume":"17","author":"HG Yu","year":"2009","unstructured":"Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behcet disease. Ocul Immunol Inflamm. 2009;17(1):41\u20136. https:\/\/doi.org\/10.1080\/09273940802553279.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"3123_CR50","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3349\/ymj.2015.56.4.1087","volume":"56","author":"M Kim","year":"2015","unstructured":"Kim M, Kwon HJ, Choi EY, Kim SS, Koh HJ, Lee SC. Correlation between Fluorescein Angiographic findings and Visual Acuity in Behcet Retinal Vasculitis. Yonsei Med J. 2015;56(4):1087\u201396. https:\/\/doi.org\/10.3349\/ymj.2015.56.4.1087.","journal-title":"Yonsei Med J"},{"issue":"8","key":"3123_CR51","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00417-008-0823-6","volume":"246","author":"I Tugal-Tutkun","year":"2008","unstructured":"Tugal-Tutkun I, Cingu K, Kir N, Yeniad B, Urgancioglu M, Gul A. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(8):1169\u201377. https:\/\/doi.org\/10.1007\/s00417-008-0823-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3123_CR52","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1002\/jcp.27207","volume":"234","author":"M Ahmadi","year":"2019","unstructured":"Ahmadi M, Yousefi M, Abbaspour-Aghdam S, Dolati S, Aghebati-Maleki L, Eghbal-Fard S, et al. Disturbed Th17\/Treg balance, cytokines, and miRNAs in peripheral blood of patients with Behcet\u2019s disease. J Cell Physiol. 2019;234(4):3985\u201394. https:\/\/doi.org\/10.1002\/jcp.27207.","journal-title":"J Cell Physiol"},{"key":"3123_CR53","doi-asserted-by":"publisher","first-page":"107812","DOI":"10.1016\/j.intimp.2021.107812","volume":"97","author":"X Cui","year":"2021","unstructured":"Cui X, Zhang L, Su G, Kijlstra A, Yang P. Specific sweat metabolite profile in ocular Behcet\u2019s disease. Int Immunopharmacol. 2021;97:107812. https:\/\/doi.org\/10.1016\/j.intimp.2021.107812.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"3123_CR54","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10787-019-00567-8","volume":"27","author":"F Djaballah-Ider","year":"2019","unstructured":"Djaballah-Ider F, Djaballah A, Djeraba Z, Chaib S, Touil-Boukoffa C. Auto-immunity profile evaluation during different clinical manifestations of Behcet disease in Algerian patients: effect of corticosteroid treatment. Inflammopharmacology. 2019;27(6):1113\u201322. https:\/\/doi.org\/10.1007\/s10787-019-00567-8.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"3123_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13075-020-02406-6","volume":"23","author":"Y Soejima","year":"2021","unstructured":"Soejima Y, Kirino Y, Takeno M, Kurosawa M, Takeuchi M, Yoshimi R, et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behcet\u2019s disease in Japan. Arthritis Res Ther. 2021;23(1):49. https:\/\/doi.org\/10.1186\/s13075-020-02406-6.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"3123_CR56","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/art.24642","volume":"61","author":"M de Menthon","year":"2009","unstructured":"de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51\/B5 and the risk of Behcet\u2019s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287\u201396. https:\/\/doi.org\/10.1002\/art.24642.","journal-title":"Arthritis Rheum"},{"issue":"24","key":"3123_CR57","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.1073\/pnas.1406575111","volume":"111","author":"MJ Ombrello","year":"2014","unstructured":"Ombrello MJ, Kirino Y, de Bakker PI, Gul A, Kastner DL, Remmers EF. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 2014;111(24):8867\u201372. https:\/\/doi.org\/10.1073\/pnas.1406575111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"3123_CR58","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1002\/art.39240","volume":"67","author":"I Sousa","year":"2015","unstructured":"Sousa I, Shahram F, Francisco D, Davatchi F, Abdollahi BS, Ghaderibarmi F, et al. Brief report: association of CCR1, KLRC4, IL12A-AS1, STAT4, and ERAP1 with Behcet\u2019s disease in iranians. Arthritis Rheumatol. 2015;67(10):2742\u20138. https:\/\/doi.org\/10.1002\/art.39240.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3123_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ng.2520","volume":"45","author":"Y Kirino","year":"2013","unstructured":"Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet\u2019s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202\u20137. https:\/\/doi.org\/10.1038\/ng.2520.","journal-title":"Nat Genet"},{"issue":"12","key":"3123_CR60","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/art.37708","volume":"64","author":"S Hou","year":"2012","unstructured":"Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a susceptibility locus in STAT4 for Behcet\u2019s disease in Han Chinese in a genome-wide association study. Arthritis Rheum. 2012;64(12):4104\u201313. https:\/\/doi.org\/10.1002\/art.37708.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3123_CR61","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2013-204475","volume":"74","author":"JM Xavier","year":"2015","unstructured":"Xavier JM, Shahram F, Sousa I, Davatchi F, Matos M, Abdollahi BS, et al. FUT2: filling the gap between genes and environment in Behcet\u2019s disease? Ann Rheum Dis. 2015;74(3):618\u201324. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204475.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3123_CR62","doi-asserted-by":"publisher","first-page":"e0119085","DOI":"10.1371\/journal.pone.0119085","volume":"10","author":"JH Kappen","year":"2015","unstructured":"Kappen JH, Medina-Gomez C, van Hagen PM, Stolk L, Estrada K, Rivadeneira F, et al. Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behcet disease. PLoS ONE. 2015;10(3):e0119085. https:\/\/doi.org\/10.1371\/journal.pone.0119085.","journal-title":"PLoS ONE"},{"issue":"8","key":"3123_CR63","doi-asserted-by":"publisher","first-page":"e0161305","DOI":"10.1371\/journal.pone.0161305","volume":"11","author":"L Ortiz-Fernandez","year":"2016","unstructured":"Ortiz-Fernandez L, Carmona FD, Montes-Cano MA, Garcia-Lozano JR, Conde-Jaldon M, Ortego-Centeno N, et al. Genetic Analysis with the Immunochip platform in Behcet Disease. Identification of residues Associated in the HLA Class I Region and New susceptibility loci. PLoS ONE. 2016;11(8):e0161305. https:\/\/doi.org\/10.1371\/journal.pone.0161305.","journal-title":"PLoS ONE"},{"issue":"8","key":"3123_CR64","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet\u2019s disease. Nat Genet. 2010;42(8):698\u2013702. https:\/\/doi.org\/10.1038\/ng.625.","journal-title":"Nat Genet"},{"issue":"2","key":"3123_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41435-022-00168-6","volume":"23","author":"XF Huang","year":"2022","unstructured":"Huang XF, Brown MA. Progress in the genetics of uveitis. Genes Immun. 2022;23(2):57\u201365. https:\/\/doi.org\/10.1038\/s41435-022-00168-6.","journal-title":"Genes Immun"},{"issue":"2","key":"3123_CR66","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaci.2016.05.024","volume":"139","author":"H Yu","year":"2017","unstructured":"Yu H, Zheng M, Zhang L, Li H, Zhu Y, Cheng L, et al. Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 for Behcet\u2019s disease in Han Chinese. J Allergy Clin Immunol. 2017;139(2):621\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2016.05.024.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3123_CR67","doi-asserted-by":"publisher","first-page":"e84214","DOI":"10.1371\/journal.pone.0084214","volume":"9","author":"Q Xiang","year":"2014","unstructured":"Xiang Q, Chen L, Hou S, Fang J, Zhou Y, Bai L, et al. TRAF5 and TRAF3IP2 gene polymorphisms are associated with Behcet\u2019s disease and vogt-koyanagi-Harada syndrome: a case-control study. PLoS ONE. 2014;9(1):e84214. https:\/\/doi.org\/10.1371\/journal.pone.0084214.","journal-title":"PLoS ONE"},{"issue":"3","key":"3123_CR68","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ng.3786","volume":"49","author":"M Takeuchi","year":"2017","unstructured":"Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet\u2019s disease susceptibility. Nat Genet. 2017;49(3):438\u201343. https:\/\/doi.org\/10.1038\/ng.3786.","journal-title":"Nat Genet"},{"issue":"9","key":"3123_CR69","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1136\/bjophthalmol-2017-311753","volume":"102","author":"P Wu","year":"2018","unstructured":"Wu P, Du L, Hou S, Su G, Yang L, Hu J, et al. Association of LACC1, CEBPB-PTPN1, RIPK2 and ADO-EGR2 with ocular Behcet\u2019s disease in a Chinese Han population. Br J Ophthalmol. 2018;102(9):1308\u201314. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311753.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"3123_CR70","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/bjophthalmol-2017-310820","volume":"102","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Li H, Hou S, Yu H, Su G, Deng B, et al. Association of genetic variations in PTPN2 and CD122 with ocular Behcet\u2019s disease. Br J Ophthalmol. 2018;102(7):996\u20131002. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310820.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3123_CR71","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1167\/iovs.11-8440","volume":"53","author":"K Hu","year":"2012","unstructured":"Hu K, Hou S, Jiang Z, Kijlstra A, Yang P. JAK2 and STAT3 polymorphisms in a Han Chinese population with Behcet\u2019s disease. Invest Ophthalmol Vis Sci. 2012;53(1):538\u201341. https:\/\/doi.org\/10.1167\/iovs.11-8440.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"3123_CR72","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1186\/ar4328","volume":"15","author":"MA Montes-Cano","year":"2013","unstructured":"Montes-Cano MA, Conde-Jaldon M, Garcia-Lozano JR, Ortiz-Fernandez L, Ortego-Centeno N, Castillo-Palma MJ, et al. HLA and non-HLA genes in Behcet\u2019s disease: a multicentric study in the Spanish population. Arthritis Res Ther. 2013;15(5):R145. https:\/\/doi.org\/10.1186\/ar4328.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"3123_CR73","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/ard.2009.119420","volume":"69","author":"Z Jiang","year":"2010","unstructured":"Jiang Z, Yang P, Hou S, Du L, Xie L, Zhou H, et al. IL-23R gene confers susceptibility to Behcet\u2019s disease in a Chinese Han population. Ann Rheum Dis. 2010;69(7):1325\u20138. https:\/\/doi.org\/10.1136\/ard.2009.119420.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3123_CR74","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/annrheumdis-2012-201627","volume":"73","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Hou S, Liang L, Li X, Tan X, Wei L, et al. MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet\u2019s disease and vogt-koyanagi-Harada syndrome. Ann Rheum Dis. 2014;73(1):170\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201627.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3123_CR75","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00109-014-1159-9","volume":"92","author":"H Yu","year":"2014","unstructured":"Yu H, Liu Y, Bai L, Kijlstra A, Yang P. Predisposition to Behcet\u2019s disease and VKH syndrome by genetic variants of miR-182. J Mol Med (Berl). 2014;92(9):961\u20137. https:\/\/doi.org\/10.1007\/s00109-014-1159-9.","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"3123_CR76","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.smim.2016.03.004","volume":"28","author":"N Thieblemont","year":"2016","unstructured":"Thieblemont N, Wright HL, Edwards SW, Witko-Sarsat V. Human neutrophils in auto-immunity. Semin Immunol. 2016;28(2):159\u2013. https:\/\/doi.org\/10.1016\/j.smim.2016.03.004. \u200973.","journal-title":"Semin Immunol"},{"key":"3123_CR77","doi-asserted-by":"publisher","unstructured":"Ley K, Hoffman HM, Kubes P, Cassatella MA, Zychlinsky A, Hedrick CC, et al. Neutrophils: new insights and open questions. Sci Immunol. 2018;3(30). https:\/\/doi.org\/10.1126\/sciimmunol.aat4579.","DOI":"10.1126\/sciimmunol.aat4579"},{"key":"3123_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.freeradbiomed.2018.03.049","volume":"125","author":"L Glennon-Alty","year":"2018","unstructured":"Glennon-Alty L, Hackett AP, Chapman EA, Wright HL. Neutrophils and redox stress in the pathogenesis of autoimmune disease. Free Radic Biol Med. 2018;125:25\u201335. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.03.049.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"3123_CR79","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jaad.2017.11.064","volume":"79","author":"CA Nelson","year":"2018","unstructured":"Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behcet disease. J Am Acad Dermatol. 2018;79(6):987\u20131006. https:\/\/doi.org\/10.1016\/j.jaad.2017.11.064.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3123_CR80","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s10067-018-4194-z","volume":"37","author":"M Hammad","year":"2018","unstructured":"Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio in Behcet\u2019s disease: which and when to use? Clin Rheumatol. 2018;37(10):2811\u20137. https:\/\/doi.org\/10.1007\/s10067-018-4194-z.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3123_CR81","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1111\/1756-185X.13404","volume":"21","author":"YH Lee","year":"2018","unstructured":"Lee YH, Song GG. Neutrophil-to-lymphocyte ratio, mean platelet volume and platelet-to-lymphocyte ratio in Behcet\u2019s disease and their correlation with disease activity: a meta-analysis. Int J Rheum Dis. 2018;21(12):2180\u20137. https:\/\/doi.org\/10.1111\/1756-185X.13404.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"3123_CR82","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","volume":"133","author":"M Becatti","year":"2016","unstructured":"Becatti M, Emmi G, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito D, et al. Neutrophil activation promotes fibrinogen oxidation and Thrombus formation in Behcet Disease. Circulation. 2016;133(3):302\u201311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017738.","journal-title":"Circulation"},{"issue":"9","key":"3123_CR83","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1136\/annrheumdis-2018-214335","volume":"78","author":"A Le Joncour","year":"2019","unstructured":"Le Joncour A, Martos R, Loyau S, Lelay N, Dossier A, Cazes A, et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet\u2019s disease. Ann Rheum Dis. 2019;78(9):1274\u201382. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214335.","journal-title":"Ann Rheum Dis"},{"key":"3123_CR84","doi-asserted-by":"publisher","first-page":"109318","DOI":"10.1016\/j.clim.2023.109318","volume":"250","author":"A Le Joncour","year":"2023","unstructured":"Le Joncour A, Cacoub P, Boulaftali Y, Saadoun D, Neutrophil. NETs and Behcet\u2019s disease: a review. Clin Immunol. 2023;250:109318. https:\/\/doi.org\/10.1016\/j.clim.2023.109318.","journal-title":"Clin Immunol"},{"issue":"1","key":"3123_CR85","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4049\/jimmunol.1800454","volume":"202","author":"S Tohme","year":"2019","unstructured":"Tohme S, Yazdani HO, Sud V, Loughran P, Huang H, Zamora R, et al. Computational analysis supports IL-17A as a central driver of Neutrophil Extracellular trap-mediated Injury in Liver Ischemia Reperfusion. J Immunol. 2019;202(1):268\u201377. https:\/\/doi.org\/10.4049\/jimmunol.1800454.","journal-title":"J Immunol"},{"issue":"1","key":"3123_CR86","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41467-022-28172-4","volume":"13","author":"AS Wilson","year":"2022","unstructured":"Wilson AS, Randall KL, Pettitt JA, Ellyard JI, Blumenthal A, Enders A, et al. Neutrophil extracellular traps and their histones promote Th17 cell differentiation directly via TLR2. Nat Commun. 2022;13(1):528. https:\/\/doi.org\/10.1038\/s41467-022-28172-4.","journal-title":"Nat Commun"},{"issue":"8","key":"3123_CR87","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41419-020-02891-2","volume":"11","author":"J Tan","year":"2020","unstructured":"Tan J, Liu H, Huang M, Li N, Tang S, Meng J, et al. Small molecules targeting RORgammat inhibit autoimmune disease by suppressing Th17 cell differentiation. Cell Death Dis. 2020;11(8):697. https:\/\/doi.org\/10.1038\/s41419-020-02891-2.","journal-title":"Cell Death Dis"},{"key":"3123_CR88","doi-asserted-by":"publisher","first-page":"590622","DOI":"10.3389\/fimmu.2020.590622","volume":"11","author":"L Li","year":"2020","unstructured":"Li L, Yu X, Liu J, Wang Z, Li C, Shi J, et al. Neutrophil Extracellular traps promote aberrant macrophages activation in Behcet\u2019s Disease. Front Immunol. 2020;11:590622. https:\/\/doi.org\/10.3389\/fimmu.2020.590622.","journal-title":"Front Immunol"},{"issue":"2","key":"3123_CR89","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2249.1990.tb05447.x","volume":"82","author":"F Fortune","year":"1990","unstructured":"Fortune F, Walker J, Lehner T. The expression of gamma delta T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behcet\u2019s syndrome. Clin Exp Immunol. 1990;82(2):326\u201332. https:\/\/doi.org\/10.1111\/j.1365-2249.1990.tb05447.x.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"3123_CR90","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1182\/blood-2003-04-1016","volume":"102","author":"M Brandes","year":"2003","unstructured":"Brandes M, Willimann K, Lang AB, Nam KH, Jin C, Brenner MB, et al. Flexible migration program regulates gamma delta T-cell involvement in humoral immunity. Blood. 2003;102(10):3693\u2013701. https:\/\/doi.org\/10.1182\/blood-2003-04-1016.","journal-title":"Blood"},{"issue":"10","key":"3123_CR91","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","volume":"11","author":"M Pineton de Chambrun","year":"2012","unstructured":"Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet\u2019s disease. Autoimmun Rev. 2012;11(10):687\u201398. https:\/\/doi.org\/10.1016\/j.autrev.2011.11.026.","journal-title":"Autoimmun Rev"},{"key":"3123_CR92","doi-asserted-by":"publisher","first-page":"705831","DOI":"10.1155\/2015\/705831","volume":"2015","author":"MS Hasan","year":"2015","unstructured":"Hasan MS, Bergmeier LA, Petrushkin H, Fortune F. Gamma Delta (gammadelta) T cells and their involvement in Behcet\u2019s Disease. J Immunol Res. 2015;2015:705831. https:\/\/doi.org\/10.1155\/2015\/705831.","journal-title":"J Immunol Res"},{"key":"3123_CR93","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fimmu.2015.00134","volume":"6","author":"H Petrushkin","year":"2015","unstructured":"Petrushkin H, Hasan MS, Stanford MR, Fortune F, Wallace GR. Behcet\u2019s Disease: do natural killer cells play a significant role? Front Immunol. 2015;6:134. https:\/\/doi.org\/10.3389\/fimmu.2015.00134.","journal-title":"Front Immunol"},{"issue":"2","key":"3123_CR94","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/cei.12939","volume":"188","author":"MS Hasan","year":"2017","unstructured":"Hasan MS, Ryan PL, Bergmeier LA, Fortune F. Circulating NK cells and their subsets in Behcet\u2019s disease. Clin Exp Immunol. 2017;188(2):311\u201322. https:\/\/doi.org\/10.1111\/cei.12939.","journal-title":"Clin Exp Immunol"},{"key":"3123_CR95","doi-asserted-by":"publisher","unstructured":"Veneziani I, Alicata C, Pelosi A, Landolina N, Ricci B, D\u2019Oria V, et al. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(-) subset. J Immunother Cancer. 2022;10(1). https:\/\/doi.org\/10.1136\/jitc-2021-003385.","DOI":"10.1136\/jitc-2021-003385"},{"key":"3123_CR96","doi-asserted-by":"publisher","first-page":"151956","DOI":"10.1016\/j.semarthrit.2022.151956","volume":"52","author":"TB van der Houwen","year":"2022","unstructured":"van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behcet\u2019s disease and treatment modalities. Semin Arthritis Rheum. 2022;52:151956. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151956.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"3123_CR97","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1615\/critrevimmunol.v25.i5.20","volume":"25","author":"MY Kimura","year":"2005","unstructured":"Kimura MY, Nakayama T. Differentiation of NK1 and NK2 cells. Crit Rev Immunol. 2005;25(5):361\u201374. https:\/\/doi.org\/10.1615\/critrevimmunol.v25.i5.20.","journal-title":"Crit Rev Immunol"},{"issue":"3","key":"3123_CR98","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/ar3005","volume":"12","author":"Y Yamaguchi","year":"2010","unstructured":"Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, et al. Natural killer cells control a T-helper 1 response in patients with Behcet\u2019s disease. Arthritis Res Ther. 2010;12(3):R80. https:\/\/doi.org\/10.1186\/ar3005.","journal-title":"Arthritis Res Ther"},{"issue":"7161","key":"3123_CR99","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419\u201326. https:\/\/doi.org\/10.1038\/nature06175.","journal-title":"Nature"},{"issue":"11","key":"3123_CR100","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/bjophthalmol-2015-307429","volume":"100","author":"AS Postole","year":"2016","unstructured":"Postole AS, Knoll AB, Auffarth GU, Mackensen F. In vivo confocal microscopy of inflammatory cells in the corneal subbasal nerve plexus in patients with different subtypes of anterior uveitis. Br J Ophthalmol. 2016;100(11):1551\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307429.","journal-title":"Br J Ophthalmol"},{"key":"3123_CR101","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.imlet.2019.03.016","volume":"209","author":"W Lin","year":"2019","unstructured":"Lin W, Liu T, Wang B, Bi H. The role of ocular dendritic cells in uveitis. Immunol Lett. 2019;209:4\u201310. https:\/\/doi.org\/10.1016\/j.imlet.2019.03.016.","journal-title":"Immunol Lett"},{"issue":"3","key":"3123_CR102","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4049\/jimmunol.1101621","volume":"188","author":"ND Heuss","year":"2012","unstructured":"Heuss ND, Lehmann U, Norbury CC, McPherson SW, Gregerson DS. Local activation of dendritic cells alters the pathogenesis of autoimmune disease in the retina. J Immunol. 2012;188(3):1191\u2013200. https:\/\/doi.org\/10.4049\/jimmunol.1101621.","journal-title":"J Immunol"},{"issue":"10","key":"3123_CR103","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.4049\/jimmunol.1600333","volume":"197","author":"Q Xiao","year":"2016","unstructured":"Xiao Q, Li X, Sun D, Yi H, Lu X, Nian H. TLR7 Engagement on dendritic cells enhances autoreactive Th17 responses via activation of ERK. J Immunol. 2016;197(10):3820\u201330. https:\/\/doi.org\/10.4049\/jimmunol.1600333.","journal-title":"J Immunol"},{"issue":"3","key":"3123_CR104","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar4570","volume":"16","author":"C Wang","year":"2014","unstructured":"Wang C, Tian Y, Ye Z, Kijlstra A, Zhou Y, Yang P. Decreased interleukin 27 expression is associated with active uveitis in Behcet\u2019s disease. Arthritis Res Ther. 2014;16(3):R117. https:\/\/doi.org\/10.1186\/ar4570.","journal-title":"Arthritis Res Ther"},{"key":"3123_CR105","doi-asserted-by":"publisher","first-page":"20401","DOI":"10.1038\/srep20401","volume":"6","author":"Z Ye","year":"2016","unstructured":"Ye Z, Deng B, Wang C, Zhang D, Kijlstra A, Yang P. Decreased B and T lymphocyte attenuator in Behcet\u2019s disease may trigger abnormal Th17 and Th1 immune responses. Sci Rep. 2016;6:20401. https:\/\/doi.org\/10.1038\/srep20401.","journal-title":"Sci Rep"},{"issue":"4 Suppl 45","key":"3123_CR106","first-page":"S34","volume":"25","author":"S Pay","year":"2007","unstructured":"Pay S, Simsek I, Erdem H, Pekel A, Musabak U, Sengul A, et al. Dendritic cell subsets and type I interferon system in Behcet\u2019s disease: does functional abnormality in plasmacytoid dendritic cells contribute to Th1 polarization? Clin Exp Rheumatol. 2007;25(4 Suppl 45):S34\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"1\u20132","key":"3123_CR107","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.imlet.2011.10.012","volume":"142","author":"TW Kim","year":"2012","unstructured":"Kim TW, Kang JS, Kong JM, Bae S, Yu Y, Chung H, et al. Maturation profiles of peripheral blood dendritic cells in patients with endogenous uveitis. Immunol Lett. 2012;142(1\u20132):14\u20139. https:\/\/doi.org\/10.1016\/j.imlet.2011.10.012.","journal-title":"Immunol Lett"},{"issue":"3","key":"3123_CR108","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/JLB.3MR0621-616RR","volume":"111","author":"YD Xu","year":"2022","unstructured":"Xu YD, Cheng M, Shang PP, Yang YQ. Role of IL-6 in dendritic cell functions. J Leukoc Biol. 2022;111(3):695\u2013709. https:\/\/doi.org\/10.1002\/JLB.3MR0621-616RR.","journal-title":"J Leukoc Biol"},{"key":"3123_CR109","doi-asserted-by":"publisher","first-page":"109303","DOI":"10.1016\/j.clim.2023.109303","volume":"250","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Yu Q, Su G, Shao N, Feng J, Luo X, et al. Interferon-alpha2a induces CD4(+) T cell apoptosis and suppresses Th1\/Th17 responses via upregulating IRF1-mediated PDL1 expression in dendritic cells from Behcet\u2019s uveitis. Clin Immunol. 2023;250:109303. https:\/\/doi.org\/10.1016\/j.clim.2023.109303.","journal-title":"Clin Immunol"},{"key":"3123_CR110","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fneur.2018.00204","volume":"9","author":"G Bitirgen","year":"2018","unstructured":"Bitirgen G, Tinkir Kayitmazbatir E, Satirtav G, Malik RA, Ozkagnici A. In Vivo Confocal Microscopic Evaluation of Corneal Nerve Fibers and dendritic cells in patients with Behcet\u2019s Disease. Front Neurol. 2018;9:204. https:\/\/doi.org\/10.3389\/fneur.2018.00204.","journal-title":"Front Neurol"},{"issue":"2","key":"3123_CR111","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0002-9394(00)00498-0","volume":"130","author":"H Keino","year":"2000","unstructured":"Keino H, Sakai J, Nishioka K, Sumida T, Usui M. Clonally accumulating T cells in the anterior chamber of Behcet disease. Am J Ophthalmol. 2000;130(2):243\u20135. https:\/\/doi.org\/10.1016\/s0002-9394(00)00498-0.","journal-title":"Am J Ophthalmol"},{"key":"3123_CR112","doi-asserted-by":"publisher","first-page":"109661","DOI":"10.1016\/j.clim.2023.109661","volume":"253","author":"AF Al-Obeidi","year":"2023","unstructured":"Al-Obeidi AF, Nowatzky J. Immunopathogenesis of Behcet\u2019s disease. Clin Immunol. 2023;253:109661. https:\/\/doi.org\/10.1016\/j.clim.2023.109661.","journal-title":"Clin Immunol"},{"key":"3123_CR113","doi-asserted-by":"publisher","first-page":"102920","DOI":"10.1016\/j.jaut.2022.102920","volume":"133","author":"Y Deng","year":"2022","unstructured":"Deng Y, Zhang Y, Cai T, Wang Q, Zhang W, Chen Z, et al. Transcriptomic profiling of iris tissue highlights LCK signaling and T cell-mediated immunity in Behcet\u2019s uveitis. J Autoimmun. 2022;133:102920. https:\/\/doi.org\/10.1016\/j.jaut.2022.102920.","journal-title":"J Autoimmun"},{"issue":"4","key":"3123_CR114","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542\u2013. https:\/\/doi.org\/10.1016\/j.immuni.2012.03.014. \u200950.","journal-title":"Immunity"},{"issue":"2","key":"3123_CR115","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/gene.2014.80","volume":"16","author":"A Tulunay","year":"2015","unstructured":"Tulunay A, Dozmorov MG, Ture-Ozdemir F, Yilmaz V, Eksioglu-Demiralp E, Alibaz-Oner F, et al. Activation of the JAK\/STAT pathway in Behcet\u2019s disease. Genes Immun. 2015;16(2):176. https:\/\/doi.org\/10.1038\/gene.2014.80.","journal-title":"Genes Immun"},{"key":"3123_CR116","doi-asserted-by":"publisher","first-page":"4246965","DOI":"10.1155\/2018\/4246965","volume":"2018","author":"A Puccetti","year":"2018","unstructured":"Puccetti A, Fiore PF, Pelosi A, Tinazzi E, Patuzzo G, Argentino G, et al. Gene expression profiling in Behcet\u2019s Disease indicates an autoimmune component in the pathogenesis of the Disease and opens New avenues for targeted therapy. J Immunol Res. 2018;2018:4246965. https:\/\/doi.org\/10.1155\/2018\/4246965.","journal-title":"J Immunol Res"},{"key":"3123_CR117","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.imlet.2018.10.013","volume":"201","author":"OM Lucherini","year":"2018","unstructured":"Lucherini OM, Lopalco G, Cantarini L, Emmi G, Lopalco A, Venerito V, et al. Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet\u2019s disease. Immunol Lett. 2018;201:38\u201344. https:\/\/doi.org\/10.1016\/j.imlet.2018.10.013.","journal-title":"Immunol Lett"},{"issue":"10","key":"3123_CR118","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1021\/pr800279m","volume":"7","author":"L Mao","year":"2008","unstructured":"Mao L, Dong H, Yang P, Zhou H, Huang X, Lin X, et al. MALDI-TOF\/TOF-MS reveals elevated serum haptoglobin and amyloid A in Behcet\u2019s disease. J Proteome Res. 2008;7(10):4500\u20137. https:\/\/doi.org\/10.1021\/pr800279m.","journal-title":"J Proteome Res"},{"issue":"6","key":"3123_CR119","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1189\/jlb.2RU1116-474R","volume":"101","author":"VB Arumugham","year":"2017","unstructured":"Arumugham VB, Baldari CT. cAMP: a multifaceted modulator of immune synapse assembly and T cell activation. J Leukoc Biol. 2017;101(6):1301\u201316. https:\/\/doi.org\/10.1189\/jlb.2RU1116-474R.","journal-title":"J Leukoc Biol"},{"issue":"Suppl 127","key":"3123_CR120","first-page":"17","volume":"38","author":"SM Kim","year":"2020","unstructured":"Kim SM, Park MJ, Park S, Cheng JY, Lee ES. Differential expression of novel genes and signalling pathways of senescent CD8\u2009+\u2009T cell subsets in Behcet\u2019s disease. Clin Exp Rheumatol. 2020;38(Suppl 127):17\u201325.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"3123_CR121","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2249.2004.02536.x","volume":"137","author":"HG Yu","year":"2004","unstructured":"Yu HG, Lee DS, Seo JM, Ahn JK, Yu YS, Lee WJ, et al. The number of CD8\u2009+\u2009T cells and NKT cells increases in the aqueous humor of patients with Behcet\u2019s uveitis. Clin Exp Immunol. 2004;137(2):437\u201343. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02536.x.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"3123_CR122","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.4049\/jimmunol.175.9.6133","volume":"175","author":"JK Ahn","year":"2005","unstructured":"Ahn JK, Chung H, Lee DS, Yu YS, Yu HG. CD8brightCD56\u2009+\u2009T cells are cytotoxic effectors in patients with active Behcet\u2019s uveitis. J Immunol. 2005;175(9):6133\u201342. https:\/\/doi.org\/10.4049\/jimmunol.175.9.6133.","journal-title":"J Immunol"},{"issue":"1","key":"3123_CR123","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3129\/i07-179","volume":"43","author":"F Ilhan","year":"2008","unstructured":"Ilhan F, Demir T, Turkcuoglu P, Turgut B, Demir N, Godekmerdan A. Th1 polarization of the immune response in uveitis in Behcet\u2019s disease. Can J Ophthalmol. 2008;43(1):105\u20138. https:\/\/doi.org\/10.3129\/i07-179.","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"3123_CR124","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jcla.21772","volume":"29","author":"ZM Akkurt","year":"2015","unstructured":"Akkurt ZM, Bozkurt M, Ucmak D, Yuksel H, Ucak H, Sula B, et al. Serum cytokine levels in Behcet\u2019s Disease. J Clin Lab Anal. 2015;29(4):317\u201320. https:\/\/doi.org\/10.1002\/jcla.21772.","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"3123_CR125","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1084\/jem.191.5.771","volume":"191","author":"MK Kennedy","year":"2000","unstructured":"Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191(5):771\u201380. https:\/\/doi.org\/10.1084\/jem.191.5.771.","journal-title":"J Exp Med"},{"issue":"3","key":"3123_CR126","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","volume":"142","author":"JK Ahn","year":"2006","unstructured":"Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behcet uveitis. Am J Ophthalmol. 2006;142(3):429\u201334. https:\/\/doi.org\/10.1016\/j.ajo.2006.04.016.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3123_CR127","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AM El-Asrar","year":"2011","unstructured":"El-Asrar AM, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139(2):177\u201384. https:\/\/doi.org\/10.1016\/j.clim.2011.01.014.","journal-title":"Clin Immunol"},{"key":"3123_CR128","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2020.00358","volume":"11","author":"M Bonacini","year":"2020","unstructured":"Bonacini M, Soriano A, Cimino L, De Simone L, Bolletta E, Gozzi F, et al. Cytokine profiling in aqueous humor samples from patients with non-infectious Uveitis Associated with systemic inflammatory diseases. Front Immunol. 2020;11:358. https:\/\/doi.org\/10.3389\/fimmu.2020.00358.","journal-title":"Front Immunol"},{"issue":"1","key":"3123_CR129","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13075-022-02867-x","volume":"24","author":"M Okubo","year":"2022","unstructured":"Okubo M, Sumitomo S, Tsuchida Y, Nagafuchi Y, Takeshima Y, Yanaoka H, et al. Transcriptome analysis of immune cells from Behcet\u2019s syndrome patients: the importance of IL-17-producing cells and antigen-presenting cells in the pathogenesis of Behcet\u2019s syndrome. Arthritis Res Ther. 2022;24(1):186. https:\/\/doi.org\/10.1186\/s13075-022-02867-x.","journal-title":"Arthritis Res Ther"},{"key":"3123_CR130","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.preteyeres.2023.101216","volume":"97","author":"Z Zhong","year":"2023","unstructured":"Zhong Z, Su G, Yang P. Risk factors, clinical features and treatment of Behcet\u2019s disease uveitis. Prog Retin Eye Res. 2023;97:101216. https:\/\/doi.org\/10.1016\/j.preteyeres.2023.101216.","journal-title":"Prog Retin Eye Res"},{"key":"3123_CR131","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.preteyeres.2020.100866","volume":"80","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2021;80:100866. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100866.","journal-title":"Prog Retin Eye Res"},{"key":"3123_CR132","doi-asserted-by":"publisher","unstructured":"Pepple KL, Lin P. Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis. Ophthalmology. 2018;125(12):1977-83. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.014.","DOI":"10.1016\/j.ophtha.2018.05.014"},{"issue":"5","key":"3123_CR133","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479\u201390. https:\/\/doi.org\/10.1016\/j.immuni.2005.09.015.","journal-title":"Immunity"},{"key":"3123_CR134","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cytogfr.2019.04.004","volume":"50","author":"X Liu","year":"2019","unstructured":"Liu X, Xiao Y, Pan Y, Li H, Zheng SG, Su W. The role of the IL-33\/ST2 axis in autoimmune disorders: friend or foe? Cytokine Growth Factor Rev. 2019;50:60\u201374. https:\/\/doi.org\/10.1016\/j.cytogfr.2019.04.004.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"3123_CR135","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3346\/jkms.2013.28.8.1145","volume":"28","author":"DJ Kim","year":"2013","unstructured":"Kim DJ, Baek SY, Park MK, Park KS, Lee JH, Park SH, et al. Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet\u2019s disease. J Korean Med Sci. 2013;28(8):1145\u201353. https:\/\/doi.org\/10.3346\/jkms.2013.28.8.1145.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"3123_CR136","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00296-014-3111-2","volume":"35","author":"SS Koca","year":"2015","unstructured":"Koca SS, Kara M, Deniz F, Ozgen M, Demir CF, Ilhan N, et al. Serum IL-33 level and IL-33 gene polymorphisms in Behcet\u2019s disease. Rheumatol Int. 2015;35(3):471\u20137. https:\/\/doi.org\/10.1007\/s00296-014-3111-2.","journal-title":"Rheumatol Int"},{"key":"3123_CR137","doi-asserted-by":"publisher","first-page":"589639","DOI":"10.3389\/fimmu.2021.589639","volume":"12","author":"M Pei","year":"2021","unstructured":"Pei M, Liu X, Yang P, Zhao C, Gao F, Qu Y, et al. Genetic Association of Interleukin 33\/ST2 polymorphisms with Behcet\u2019s Uveitis. Front Immunol. 2021;12:589639. https:\/\/doi.org\/10.3389\/fimmu.2021.589639.","journal-title":"Front Immunol"},{"issue":"6","key":"3123_CR138","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3892\/br.2017.996","volume":"7","author":"JY Yoon","year":"2017","unstructured":"Yoon JY, Lee Y, Yu SL, Yoon HK, Park HY, Joung CI, et al. Aberrant expression of interleukin-10 and activation-induced cytidine deaminase in B cells from patients with Behcet\u2019s disease. Biomed Rep. 2017;7(6):520\u20136. https:\/\/doi.org\/10.3892\/br.2017.996.","journal-title":"Biomed Rep"},{"issue":"1","key":"3123_CR139","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/rheumatology\/kew366","volume":"56","author":"TB van der Houwen","year":"2017","unstructured":"van der Houwen TB, van Hagen PM, Timmermans WM, Bartol SJ, Lam KH, Kappen JH, et al. Chronic signs of memory B cell activation in patients with Behcet\u2019s disease are partially restored by anti-tumour necrosis factor treatment. Rheumatology (Oxford). 2017;56(1):134\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/kew366.","journal-title":"Rheumatology (Oxford)"},{"key":"3123_CR140","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/JIR.S279912","volume":"14","author":"HF Hetta","year":"2021","unstructured":"Hetta HF, Mohamed AAA, Zahran AM, My Sayed SAM, Ga Saleh M. Possible role of Regulatory B cells in different Behcet\u2019s Disease Phenotypes and therapies: First Report from Egypt. J Inflamm Res. 2021;14:737\u201344. https:\/\/doi.org\/10.2147\/JIR.S279912.","journal-title":"J Inflamm Res"},{"key":"3123_CR141","doi-asserted-by":"publisher","first-page":"109304","DOI":"10.1016\/j.clim.2023.109304","volume":"250","author":"A Bettiol","year":"2023","unstructured":"Bettiol A, Emmi G, Low L, Sofi F, Wallace GR. Microbiome in Behcet\u2019s syndrome. Clin Immunol. 2023;250:109304. https:\/\/doi.org\/10.1016\/j.clim.2023.109304.","journal-title":"Clin Immunol"},{"issue":"3","key":"3123_CR142","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cell.2009.09.033","volume":"139","author":"II Ivanov","year":"2009","unstructured":"Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485\u201398. https:\/\/doi.org\/10.1016\/j.cell.2009.09.033.","journal-title":"Cell"},{"issue":"5","key":"3123_CR143","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nri2515","volume":"9","author":"JL Round","year":"2009","unstructured":"Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313\u201323. https:\/\/doi.org\/10.1038\/nri2515.","journal-title":"Nat Rev Immunol"},{"issue":"7461","key":"3123_CR144","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12331","volume":"500","author":"K Atarashi","year":"2013","unstructured":"Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232\u20136. https:\/\/doi.org\/10.1038\/nature12331.","journal-title":"Nature"},{"issue":"7","key":"3123_CR145","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s10067-015-2966-2","volume":"35","author":"J Shimizu","year":"2016","unstructured":"Shimizu J, Takai K, Takada E, Fujiwara N, Arimitsu N, Ueda Y, et al. Possible association of proinflammatory cytokines including IL1beta and TNFalpha with enhanced Th17 cell differentiation in patients with Behcet\u2019s disease. Clin Rheumatol. 2016;35(7):1857\u201363. https:\/\/doi.org\/10.1007\/s10067-015-2966-2.","journal-title":"Clin Rheumatol"},{"key":"3123_CR146","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3389\/fimmu.2020.01192","volume":"11","author":"TB van der Houwen","year":"2020","unstructured":"van der Houwen TB, van Laar JAM, Kappen JH, van Hagen PM, de Zoete MR, van Muijlwijk GH, et al. Behcet\u2019s Disease under Microbiotic Surveillance? A combined analysis of two cohorts of Behcet\u2019s Disease patients. Front Immunol. 2020;11:1192. https:\/\/doi.org\/10.3389\/fimmu.2020.01192.","journal-title":"Front Immunol"},{"issue":"5","key":"3123_CR147","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10067-018-04419-8","volume":"38","author":"J Shimizu","year":"2019","unstructured":"Shimizu J, Kubota T, Takada E, Takai K, Fujiwara N, Arimitsu N, et al. Relative abundance of Megamonas hypermegale and Butyrivibrio species decreased in the intestine and its possible association with the T cell aberration by metabolite alteration in patients with Behcet\u2019s disease (210 characters). Clin Rheumatol. 2019;38(5):1437\u201345. https:\/\/doi.org\/10.1007\/s10067-018-04419-8.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3123_CR148","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40168-018-0520-6","volume":"6","author":"Z Ye","year":"2018","unstructured":"Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, et al. A metagenomic study of the gut microbiome in Behcet\u2019s disease. Microbiome. 2018;6(1):135. https:\/\/doi.org\/10.1186\/s40168-018-0520-6.","journal-title":"Microbiome"},{"issue":"6145","key":"3123_CR149","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569\u201373. https:\/\/doi.org\/10.1126\/science.1241165.","journal-title":"Science"},{"key":"3123_CR150","doi-asserted-by":"publisher","first-page":"716760","DOI":"10.3389\/fcell.2021.716760","volume":"9","author":"Q Wang","year":"2021","unstructured":"Wang Q, Yi S, Su G, Du Z, Pan S, Huang X, et al. Changes in the gut Microbiome Contribute to the development of Behcet\u2019s Disease via Adjuvant effects. Front Cell Dev Biol. 2021;9:716760. https:\/\/doi.org\/10.3389\/fcell.2021.716760.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"3123_CR151","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/jamaophthalmol.2020.6985","volume":"139","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Su G, Zhou Q, Meguro A, Takeuchi M, Mizuki N, et al. Tuberculosis exposure with risk of Behcet Disease among patients with Uveitis. JAMA Ophthalmol. 2021;139(4):415\u201322. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.6985.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"3123_CR152","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1365-3083.1996.d01-53.x","volume":"43","author":"H Direskeneli","year":"1996","unstructured":"Direskeneli H, Hasan A, Shinnick T, Mizushima R, van der Zee R, Fortune F, et al. Recognition of B-cell epitopes of the 65\u00a0kDa HSP in Behcet\u2019s disease. Scand J Immunol. 1996;43(4):464\u201371. https:\/\/doi.org\/10.1046\/j.1365-3083.1996.d01-53.x.","journal-title":"Scand J Immunol"},{"issue":"2","key":"3123_CR153","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1076\/ocii.7.2.69.4018","volume":"7","author":"T Tanaka","year":"1999","unstructured":"Tanaka T, Yamakawa N, Koike N, Suzuki J, Mizuno F, Usui M. Behcet\u2019s disease and antibody titers to various heat-shock protein 60s. Ocul Immunol Inflamm. 1999;7(2):69\u201374. https:\/\/doi.org\/10.1076\/ocii.7.2.69.4018.","journal-title":"Ocul Immunol Inflamm"},{"key":"3123_CR154","doi-asserted-by":"publisher","first-page":"968345","DOI":"10.3389\/fmed.2022.968345","volume":"9","author":"SH Aboul Naga","year":"2022","unstructured":"Aboul Naga SH, Hassan LM, El Zanaty RT, Refaat M, Amin RH, Ragab G, et al. Behcet uveitis: current practice and future perspectives. Front Med (Lausanne). 2022;9:968345. https:\/\/doi.org\/10.3389\/fmed.2022.968345.","journal-title":"Front Med (Lausanne)"},{"issue":"7\u20138","key":"3123_CR155","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1080\/09273948.2021.1960381","volume":"30","author":"H Tan","year":"2022","unstructured":"Tan H, Pan S, Zhong Z, Su G, Kijlstra A, Yang P. Association between Fine Particulate Air Pollution and the onset of Uveitis in Mainland China. Ocul Immunol Inflamm. 2022;30(7\u20138):1810\u20135. https:\/\/doi.org\/10.1080\/09273948.2021.1960381.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"3123_CR156","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1186\/s12889-023-16591-x","volume":"23","author":"H Tan","year":"2023","unstructured":"Tan H, Feng X, Yang P. Association between uveitis onset and economic development in mainland China. BMC Public Health. 2023;23(1):1711. https:\/\/doi.org\/10.1186\/s12889-023-16591-x.","journal-title":"BMC Public Health"},{"issue":"Suppl 1","key":"3123_CR157","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.3109\/09273948.2014.981547","volume":"23","author":"K Namba","year":"2015","unstructured":"Namba K, Goto H, Kaburaki T, Kitaichi N, Mizuki N, Asukata Y, et al. A major review: current aspects of ocular Behcet\u2019s Disease in Japan. Ocul Immunol Inflamm. 2015;23(Suppl 1):S1\u201323. https:\/\/doi.org\/10.3109\/09273948.2014.981547.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"3123_CR158","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","volume":"90","author":"H Ideguchi","year":"2011","unstructured":"Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Med (Baltim). 2011;90(2):125\u201332. https:\/\/doi.org\/10.1097\/MD.0b013e318211bf28.","journal-title":"Med (Baltim)"},{"issue":"4","key":"3123_CR159","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4274\/tjo.galenos.2020.28485","volume":"51","author":"FN Yalcindag","year":"2021","unstructured":"Yalcindag FN, Cakar Ozdal P, Ozyazgan Y, Batioglu F, Tugal-Tutkun I. Comparison of Sociodemographic Features between Behcet Uveitis and other non-infectious Uveitis. Turk J Ophthalmol. 2021;51(4):206\u201311. https:\/\/doi.org\/10.4274\/tjo.galenos.2020.28485.","journal-title":"Turk J Ophthalmol"},{"key":"3123_CR160","doi-asserted-by":"publisher","unstructured":"Dang J, Shi D, Li X, Ma N, Liu Y, Zhong P, et al. Artificial Light-at-night exposure and overweight and obesity across GDP levels among Chinese children and adolescents. Nutrients. 2023;15(4). https:\/\/doi.org\/10.3390\/nu15040939.","DOI":"10.3390\/nu15040939"},{"issue":"4","key":"3123_CR161","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","volume":"3","author":"A Consolaro","year":"2019","unstructured":"Consolaro A, Giancane G, Alongi A, van Dijkhuizen EHP, Aggarwal A, Al-Mayouf SM, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019;3(4):255\u201363. https:\/\/doi.org\/10.1016\/S2352-4642(19)30027-6.","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"3123_CR162","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.rpsm.2017.07.006","volume":"11","author":"V Soria","year":"2018","unstructured":"Soria V, Uribe J, Salvat-Pujol N, Palao D, Menchon JM, Labad J. Psychoneuroimmunology of mental disorders. Rev Psiquiatr Salud Ment (Engl Ed). 2018;11(2):115\u201324. https:\/\/doi.org\/10.1016\/j.rpsm.2017.07.006.","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"issue":"2","key":"3123_CR163","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ajo.2013.10.010","volume":"157","author":"J Fang","year":"2014","unstructured":"Fang J, Hou S, Xiang Q, Qi J, Yu H, Shi Y, et al. Polymorphisms in genetics of vitamin D metabolism confer susceptibility to ocular Behcet disease in a Chinese Han population. Am J Ophthalmol. 2014;157(2):488\u2013. https:\/\/doi.org\/10.1016\/j.ajo.2013.10.010. 94 e6.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"3123_CR164","doi-asserted-by":"publisher","first-page":"6434","DOI":"10.1167\/iovs.12-10398","volume":"53","author":"Y Tian","year":"2012","unstructured":"Tian Y, Wang C, Ye Z, Xiao X, Kijlstra A, Yang P. Effect of 1,25-dihydroxyvitamin D3 on Th17 and Th1 response in patients with Behcet\u2019s disease. Invest Ophthalmol Vis Sci. 2012;53(10):6434\u201341. https:\/\/doi.org\/10.1167\/iovs.12-10398.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"3123_CR165","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ophtha.2009.08.011","volume":"117","author":"P Lin","year":"2010","unstructured":"Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010;117(3):585\u2013. https:\/\/doi.org\/10.1016\/j.ophtha.2009.08.011. \u200990.","journal-title":"Ophthalmology"},{"issue":"1","key":"3123_CR166","doi-asserted-by":"publisher","first-page":"12156","DOI":"10.1038\/s41598-021-91701-6","volume":"11","author":"N Neti","year":"2021","unstructured":"Neti N, Pimsri A, Boonsopon S, Tesavibul N, Choopong P. Triggering factors associated with a new episode of recurrent acute anterior uveitis. Sci Rep. 2021;11(1):12156. https:\/\/doi.org\/10.1038\/s41598-021-91701-6.","journal-title":"Sci Rep"},{"issue":"2","key":"3123_CR167","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaophthalmol.2018.5893","volume":"137","author":"EJ Berlinberg","year":"2019","unstructured":"Berlinberg EJ, Gonzales JA, Doan T, Acharya NR. Association between Noninfectious Uveitis and psychological stress. JAMA Ophthalmol. 2019;137(2):199\u2013205. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.5893.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"3123_CR168","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/09273948.2019.1681469","volume":"29","author":"A Gomez-Gomez","year":"2021","unstructured":"Gomez-Gomez A, Garcia-Gonzalez J, Peiteado D, Borrego-Sanz L, Arriola-Villalobos P, Esteban-Ortega M, et al. Inflammatory relapses after immunosuppressive drug discontinuation in Uveitis patients: a survival analysis. Ocul Immunol Inflamm. 2021;29(2):376\u201387. https:\/\/doi.org\/10.1080\/09273948.2019.1681469.","journal-title":"Ocul Immunol Inflamm"},{"key":"3123_CR169","doi-asserted-by":"publisher","first-page":"911951","DOI":"10.3389\/fimmu.2022.911951","volume":"13","author":"DC Malherbe","year":"2022","unstructured":"Malherbe DC, Messaoudi I. Transcriptional and epigenetic regulation of Monocyte and Macrophage Dysfunction by Chronic Alcohol Consumption. Front Immunol. 2022;13:911951. https:\/\/doi.org\/10.3389\/fimmu.2022.911951.","journal-title":"Front Immunol"},{"issue":"1","key":"3123_CR170","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/BOR.0000000000000854","volume":"34","author":"G Hatemi","year":"2022","unstructured":"Hatemi G. A treat-to-target approach is needed for Behcet\u2019s syndrome. Curr Opin Rheumatol. 2022;34(1):39\u201345. https:\/\/doi.org\/10.1097\/BOR.0000000000000854.","journal-title":"Curr Opin Rheumatol"},{"key":"3123_CR171","doi-asserted-by":"crossref","unstructured":"Yang P. Atlas of Uveitis: diagnosis and treatment. Springer; 2021.","DOI":"10.1007\/978-981-15-3726-4"},{"issue":"9","key":"3123_CR172","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/1756-185X.13095","volume":"20","author":"M Mohammadi","year":"2017","unstructured":"Mohammadi M, Shahram F, Shams H, Akhlaghi M, Ashofteh F, Davatchi F. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet\u2019s disease: a pilot double-blind controlled study. Int J Rheum Dis. 2017;20(9):1269\u201376. https:\/\/doi.org\/10.1111\/1756-185X.13095.","journal-title":"Int J Rheum Dis"},{"key":"3123_CR173","doi-asserted-by":"publisher","first-page":"109633","DOI":"10.1016\/j.clim.2023.109633","volume":"251","author":"T Tao","year":"2023","unstructured":"Tao T, Yang S, He D, Li Z, Chen B, Zhu L, et al. Intravitreal dexamethasone implants facilitate the management of refractory Behcet\u2019s uveitis with vasculitis. Clin Immunol. 2023;251:109633. https:\/\/doi.org\/10.1016\/j.clim.2023.109633.","journal-title":"Clin Immunol"},{"issue":"5","key":"3123_CR174","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14712598.2019.1595578","volume":"19","author":"S Touhami","year":"2019","unstructured":"Touhami S, Diwo E, Seve P, Trad S, Bielefeld P, Sene D, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477\u201390. https:\/\/doi.org\/10.1080\/14712598.2019.1595578.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"3123_CR175","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet\u2019s syndrome. N Engl J Med. 1990;322(5):281\u20135. https:\/\/doi.org\/10.1056\/NEJM199002013220501.","journal-title":"N Engl J Med"},{"issue":"4","key":"3123_CR176","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, et al. Low dose cyclosporin a versus pulsed cyclophosphamide in Behcet\u2019s syndrome: a single masked trial. Br J Ophthalmol. 1992;76(4):241\u20133. https:\/\/doi.org\/10.1136\/bjo.76.4.241.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"3123_CR177","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/acr.20308","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche-Rigon M, et al. Azathioprine in severe uveitis of Behcet\u2019s disease. Arthritis Care Res (Hoboken). 2010;62(12):1733\u20138. https:\/\/doi.org\/10.1002\/acr.20308.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8647","key":"3123_CR178","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet\u2019s disease. Lancet. 1989;1(8647):1093\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(89)92381-7.","journal-title":"Lancet"},{"key":"3123_CR179","doi-asserted-by":"publisher","first-page":"699903","DOI":"10.3389\/fphar.2021.699903","volume":"12","author":"Y Qian","year":"2021","unstructured":"Qian Y, Qu Y, Gao F, Pei M, Liang A, Xiao J, et al. Comparison of the Safety and Efficacy of Interferon Alpha-2a and Cyclosporine-A when combined with glucocorticoid in the Treatment of Refractory Behcet\u2019s Uveitis: a randomized controlled prospective study. Front Pharmacol. 2021;12:699903. https:\/\/doi.org\/10.3389\/fphar.2021.699903.","journal-title":"Front Pharmacol"},{"key":"3123_CR180","first-page":"880","volume":"16","author":"W Chi","year":"2010","unstructured":"Chi W, Yang P, Zhu X, Wang Y, Chen L, Huang X, et al. Production of interleukin-17 in Behcet\u2019s disease is inhibited by cyclosporin A. Mol Vis. 2010;16:880\u20136.","journal-title":"Mol Vis"},{"issue":"4 Suppl 50","key":"3123_CR181","first-page":"S84","volume":"26","author":"G Akman-Demir","year":"2008","unstructured":"Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behcet\u2019s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(4 Suppl 50):S84\u201390.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"3123_CR182","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/1756-185X.12139","volume":"16","author":"F Davatchi","year":"2013","unstructured":"Davatchi F, Shams H, Shahram F, Nadji A, Chams-Davatchi C, Sadeghi Abdollahi B, et al. Methotrexate in ocular manifestations of Behcet\u2019s disease: a longitudinal study up to 15 years. Int J Rheum Dis. 2013;16(5):568\u201377. https:\/\/doi.org\/10.1111\/1756-185X.12139.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"3123_CR183","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0161-6420(01)00864-8","volume":"109","author":"E Miserocchi","year":"2002","unstructured":"Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and ear infirmary experience. Ophthalmology. 2002;109(1):137\u201342. https:\/\/doi.org\/10.1016\/s0161-6420(01)00864-8.","journal-title":"Ophthalmology"},{"issue":"1","key":"3123_CR184","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1590\/s0004-27492010000100007","volume":"73","author":"JM Zaghetto","year":"2010","unstructured":"Zaghetto JM, Yamamoto MM, Souza MB, Silva FT, Hirata CE, Olivalves E, et al. Chlorambucil and cyclosporine A in Brazilian patients with Behcet\u2019s disease uveitis: a retrospective study. Arq Bras Oftalmol. 2010;73(1):40\u20136. https:\/\/doi.org\/10.1590\/s0004-27492010000100007.","journal-title":"Arq Bras Oftalmol"},{"issue":"6","key":"3123_CR185","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/bjo.74.6.353","volume":"74","author":"HH Tessler","year":"1990","unstructured":"Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet\u2019s disease. Br J Ophthalmol. 1990;74(6):353\u20137. https:\/\/doi.org\/10.1136\/bjo.74.6.353.","journal-title":"Br J Ophthalmol"},{"key":"3123_CR186","doi-asserted-by":"publisher","unstructured":"Lu A, Liu Z, Su G, Yang P. Global Research Status regarding Uveitis in the last decade. Ocul Immunol Inflamm 2023:1\u201310. https:\/\/doi.org\/10.1080\/09273948.2023.2170251.","DOI":"10.1080\/09273948.2023.2170251"},{"issue":"3","key":"3123_CR187","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785\u2013. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.048. \u200996 e3.","journal-title":"Ophthalmology"},{"key":"3123_CR188","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","volume":"238","author":"G Maalouf","year":"2022","unstructured":"Maalouf G, Andrillon A, Leclercq M, Seve P, Bielefeld P, Gueudry J, et al. Lower relapses Rate with Infliximab Versus Adalimumab in Sight-threatening Uveitis: a Multicenter Study of 330 patients. Am J Ophthalmol. 2022;238:173\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.002.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"3123_CR189","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362\u20138.","journal-title":"J Rheumatol"},{"issue":"2","key":"3123_CR190","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"K Takase","year":"2011","unstructured":"Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int. 2011;31(2):243\u20135. https:\/\/doi.org\/10.1007\/s00296-009-1178-y.","journal-title":"Rheumatol Int"},{"issue":"8","key":"3123_CR191","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M Diaz-Llopis","year":"2012","unstructured":"Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, Cordero-Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575\u201381. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.018.","journal-title":"Ophthalmology"},{"key":"3123_CR192","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Behcet\u2019s disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005.","journal-title":"J Autoimmun"},{"issue":"1","key":"3123_CR193","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","volume":"30","author":"K Kunimi","year":"2022","unstructured":"Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, et al. Anti-TNF-alpha Therapy for Refractory Uveitis Associated with Behcet\u2019s syndrome and sarcoidosis: a single Center Study of 131 patients. Ocul Immunol Inflamm. 2022;30(1):223\u201330. https:\/\/doi.org\/10.1080\/09273948.2020.1791346.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"3123_CR194","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1111\/aos.13699","volume":"96","author":"I Leal","year":"2018","unstructured":"Leal I, Rodrigues FB, Sousa DC, Romao VC, Duarte GS, Carreno E, et al. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. Acta Ophthalmol. 2018;96(6):e665\u201375. https:\/\/doi.org\/10.1111\/aos.13699.","journal-title":"Acta Ophthalmol"},{"key":"3123_CR195","doi-asserted-by":"publisher","first-page":"109242","DOI":"10.1016\/j.clim.2023.109242","volume":"247","author":"TB van der Houwen","year":"2023","unstructured":"van der Houwen TB, Humer B, Missotten TO, Thiadens A, van Hagen PM, van Laar JAM. Long-term data on efficacy and safety of adalimumab in Behcet\u2019s disease. Clin Immunol. 2023;247:109242. https:\/\/doi.org\/10.1016\/j.clim.2023.109242.","journal-title":"Clin Immunol"},{"issue":"5","key":"3123_CR196","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","volume":"102","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Sota J, Vitale A, Rigante D, Emmi G, Vannozzi L, et al. Cumulative retention rate of adalimumab in patients with Behcet\u2019s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102(5):637\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310733.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3123_CR197","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10067-018-4069-3","volume":"38","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Emmi G, Bitossi A, Lopalco G, Sota J, et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol. 2019;38(1):63\u201370. https:\/\/doi.org\/10.1007\/s10067-018-4069-3.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3123_CR198","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, Demetrio-Pablo R, Beltran E, Sanchez-Burson J, et al. Comparative study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet\u2019s Disease: National Multicenter Study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081\u20139. https:\/\/doi.org\/10.1002\/art.41026.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"3123_CR199","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1509852.","journal-title":"N Engl J Med"},{"key":"3123_CR200","doi-asserted-by":"publisher","first-page":"107430","DOI":"10.1016\/j.intimp.2021.107430","volume":"93","author":"S Yang","year":"2021","unstructured":"Yang S, Huang Z, Liu X, Li H, Xie L, Chen X, et al. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behcet\u2019s uveitis with vasculitis. Int Immunopharmacol. 2021;93:107430. https:\/\/doi.org\/10.1016\/j.intimp.2021.107430.","journal-title":"Int Immunopharmacol"},{"issue":"9278","key":"3123_CR201","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease. Lancet. 2001;358(9278):295\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(01)05497-6.","journal-title":"Lancet"},{"issue":"5","key":"3123_CR202","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3899\/jrheum.200300","volume":"48","author":"JL Martin-Varillas","year":"2021","unstructured":"Martin-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltran E, Sanchez-Burson J, Adan A, et al. Long-term follow-up and optimization of Infliximab in Refractory Uveitis due to Behcet Disease: National Study of 103 White patients. J Rheumatol. 2021;48(5):741\u201350. https:\/\/doi.org\/10.3899\/jrheum.200300.","journal-title":"J Rheumatol"},{"issue":"5","key":"3123_CR203","doi-asserted-by":"publisher","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140(5):404\u20136. https:\/\/doi.org\/10.7326\/0003-4819-140-5-200403020-00025.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3123_CR204","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/MAJ.0b013e3180318fbc","volume":"27","author":"PG Theodossiadis","year":"2007","unstructured":"Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27(4):399\u2013413. https:\/\/doi.org\/10.1097\/MAJ.0b013e3180318fbc.","journal-title":"Retina"},{"issue":"1","key":"3123_CR205","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61\u201370. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.09.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3123_CR206","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, et al. Ten-year Retention Rate of Infliximab in patients with Behcet\u2019s Disease-Related Uveitis. Ocul Immunol Inflamm. 2019;27(1):34\u20139. https:\/\/doi.org\/10.1080\/09273948.2017.1391297.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"3123_CR207","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","volume":"28","author":"N Yalcindag","year":"2020","unstructured":"Yalcindag N, Kose HC. Comparison of the treatment results for Behcet Uveitis in patients treated with Infliximab and Interferon. Ocul Immunol Inflamm. 2020;28(2):305\u201314. https:\/\/doi.org\/10.1080\/09273948.2019.1606256.","journal-title":"Ocul Immunol Inflamm"},{"issue":"Suppl 108","key":"3123_CR208","first-page":"86","volume":"35","author":"G Guzelant","year":"2017","unstructured":"Guzelant G, Ucar D, Esatoglu SN, Hatemi G, Ozyazgan Y, Yurdakul S, et al. Infliximab for uveitis of Behcet\u2019s syndrome: a trend for earlier initiation. Clin Exp Rheumatol. 2017;35(Suppl 108):86\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"3123_CR209","doi-asserted-by":"publisher","first-page":"109263","DOI":"10.1016\/j.clim.2023.109263","volume":"248","author":"T Bozkurt","year":"2023","unstructured":"Bozkurt T, Karabacak M, Karatas H, Kutlug Agackiran S, Ergun T, Direskeneli H, et al. Earlier and more aggressive treatment with biologics may prevent relapses and further new organ involvement in Behcet\u2019s disease. Clin Immunol. 2023;248:109263. https:\/\/doi.org\/10.1016\/j.clim.2023.109263.","journal-title":"Clin Immunol"},{"issue":"6","key":"3123_CR210","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10384-021-00872-2","volume":"65","author":"Y Ida","year":"2021","unstructured":"Ida Y, Takeuchi M, Ishihara M, Shibuya E, Yamane T, Hasumi Y, et al. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behcet\u2019s disease in long-term remission. Jpn J Ophthalmol. 2021;65(6):843\u20138. https:\/\/doi.org\/10.1007\/s10384-021-00872-2.","journal-title":"Jpn J Ophthalmol"},{"key":"3123_CR211","doi-asserted-by":"publisher","unstructured":"Okada K, Zhou Y, Hashida N, Takagi T, Tian YS. The efficacy of Golimumab against non-infectious uveitis: a PRISMA-compliant systematic review and meta-analysis. Ocul Immunol Inflamm 2022:1\u201311. https:\/\/doi.org\/10.1080\/09273948.2022.2081584.","DOI":"10.1080\/09273948.2022.2081584"},{"issue":"1","key":"3123_CR212","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, et al. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behcet\u2019s Disease. Ocul Immunol Inflamm. 2019;27(1):58\u201363. https:\/\/doi.org\/10.1080\/09273948.2017.1351573.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"3123_CR213","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s10787-022-01019-6","volume":"30","author":"Y Jin","year":"2022","unstructured":"Jin Y, Lu S, Lin Y, Mou X. The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacology. 2022;30(4):1363\u20138. https:\/\/doi.org\/10.1007\/s10787-022-01019-6.","journal-title":"Inflammopharmacology"},{"issue":"4","key":"3123_CR214","first-page":"680","volume":"37","author":"GM Tosi","year":"2019","unstructured":"Tosi GM, Sota J, Vitale A, Rigante D, Emmi G, Lopalco G, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37(4):680\u20133.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3123_CR215","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0165-0378(97)00068-5","volume":"37","author":"NE Simister","year":"1997","unstructured":"Simister NE, Story CM. Human placental fc receptors and the transmission of antibodies from mother to fetus. J Reprod Immunol. 1997;37(1):1\u201323. https:\/\/doi.org\/10.1016\/s0165-0378(97)00068-5.","journal-title":"J Reprod Immunol"},{"issue":"1","key":"3123_CR216","doi-asserted-by":"publisher","first-page":"105","DOI":"10.55563\/clinexprheumatol\/j9ysbm","volume":"39","author":"D Prieto-Pena","year":"2021","unstructured":"Prieto-Pena D, Calderon-Goercke M, Adan A, Chamorro-Lopez L, Maiz-Alonso O, De Dios-Jimenez Aberasturi JR, et al. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clin Exp Rheumatol. 2021;39(1):105\u201314. https:\/\/doi.org\/10.55563\/clinexprheumatol\/j9ysbm.","journal-title":"Clin Exp Rheumatol"},{"key":"3123_CR217","doi-asserted-by":"publisher","first-page":"912906","DOI":"10.3389\/fphar.2022.912906","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Shi X, Ren Y, Yan T, Ye Q. Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behcet\u2019s disease: a systematic review of controlled trials. Front Pharmacol. 2022;13:912906. https:\/\/doi.org\/10.3389\/fphar.2022.912906.","journal-title":"Front Pharmacol"},{"issue":"9","key":"3123_CR218","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","volume":"21","author":"DM Nathan","year":"2006","unstructured":"Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21(9):1366\u201371. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04559.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"3123_CR219","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","volume":"77","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Aksamit AJ Jr., Davis JM 3rd, Kantarci OH, Keegan BM, Pittock SJ, et al. Association between Tumor Necrosis Factor Inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937\u201346. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1162.","journal-title":"JAMA Neurol"},{"issue":"4","key":"3123_CR220","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10067-016-3528-y","volume":"36","author":"S Monti","year":"2017","unstructured":"Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, et al. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017;36(4):753\u201361. https:\/\/doi.org\/10.1007\/s10067-016-3528-y.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"3123_CR221","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I Kotter","year":"2003","unstructured":"Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423\u201331. https:\/\/doi.org\/10.1136\/bjo.87.4.423.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3123_CR222","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/bjo.82.5.488","volume":"82","author":"I Kotter","year":"1998","unstructured":"Kotter I, Eckstein AK, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behcet\u2019s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol. 1998;82(5):488\u201394. https:\/\/doi.org\/10.1136\/bjo.82.5.488.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3123_CR223","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1167\/iovs.18-25548","volume":"60","author":"O Albayrak","year":"2019","unstructured":"Albayrak O, Oray M, Can F, Uludag Kirimli G, Gul A, Tugal-Tutkun I, et al. Effect of Interferon alfa-2a treatment on adaptive and innate Immune systems in patients with Behcet Disease Uveitis. Invest Ophthalmol Vis Sci. 2019;60(1):52\u201363. https:\/\/doi.org\/10.1167\/iovs.18-25548.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3123_CR224","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/rheumatology\/keq330","volume":"50","author":"X Liu","year":"2011","unstructured":"Liu X, Yang P, Wang C, Li F, Kijlstra A. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet\u2019s disease. Rheumatology (Oxford). 2011;50(2):293\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keq330.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3123_CR225","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr., Brezin AP, Chee SP, et al. Guidance on Noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of Care for UveitiS (FOCUS). Initiative Ophthalmol. 2018;125(5):757\u201373. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.017.","journal-title":"Initiative Ophthalmol"},{"issue":"3","key":"3123_CR226","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/09273948.2019.1587473","volume":"28","author":"H Eser-Ozturk","year":"2020","unstructured":"Eser-Ozturk H, Sullu Y. The results of Interferon-Alpha treatment in Behcet Uveitis. Ocul Immunol Inflamm. 2020;28(3):498\u2013504. https:\/\/doi.org\/10.1080\/09273948.2019.1587473.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"3123_CR227","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/09273948.2020.1815797","volume":"30","author":"L De Simone","year":"2022","unstructured":"De Simone L, Invernizzi A, Aldigeri R, Mastrofilippo V, Marvisi C, Gozzi F, et al. Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behcet\u2019s Uveitis: customizing therapy according to the clinical features. Ocul Immunol Inflamm. 2022;30(2):506\u201314. https:\/\/doi.org\/10.1080\/09273948.2020.1815797.","journal-title":"Ocul Immunol Inflamm"},{"key":"3123_CR228","doi-asserted-by":"publisher","first-page":"204062231984788","DOI":"10.1177\/2040622319847881","volume":"10","author":"J Shi","year":"2019","unstructured":"Shi J, Zhao C, Zhou J, Liu J, Wang L, Gao F, et al. Effectiveness and safety of interferon alpha2a as an add-on treatment for refractory Behcet\u2019s uveitis. Ther Adv Chronic Dis. 2019;10:2040622319847881. https:\/\/doi.org\/10.1177\/2040622319847881.","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"3123_CR229","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","volume":"25","author":"E Diwo","year":"2017","unstructured":"Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of Interferon in severe Uveitis Associated with Behcet Disease. Ocul Immunol Inflamm. 2017;25(1):76\u201384. https:\/\/doi.org\/10.1080\/09273948.2016.1206204.","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"3123_CR230","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CM Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet\u2019s disease. Arthritis Rheum. 2010;62(9):2796\u2013805. https:\/\/doi.org\/10.1002\/art.27581.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3123_CR231","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/09273948.2017.1332768","volume":"27","author":"H Celiker","year":"2019","unstructured":"Celiker H, Kazokoglu H, Direskeneli H. Long-term efficacy of Pegylated Interferon Alpha-2b in Behcet\u2019s Uveitis: a small Case Series. Ocul Immunol Inflamm. 2019;27(1):15\u201322. https:\/\/doi.org\/10.1080\/09273948.2017.1332768.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"3123_CR232","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246\u201352. https:\/\/doi.org\/10.1111\/j.1756-185X.2010.01546.x.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"3123_CR233","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12348-021-00252-4","volume":"11","author":"CC Ng","year":"2021","unstructured":"Ng CC, Sy A, Cunningham ET. Jr. Rituximab for non-infectious Uveitis and Scleritis. J Ophthalmic Inflamm Infect. 2021;11(1):23. https:\/\/doi.org\/10.1186\/s12348-021-00252-4.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"12","key":"3123_CR234","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","volume":"191","author":"X Zhang","year":"2013","unstructured":"Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191(12):5867\u201374. https:\/\/doi.org\/10.4049\/jimmunol.1301926.","journal-title":"J Immunol"},{"issue":"10","key":"3123_CR235","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3899\/jrheum.141344","volume":"42","author":"AJ Mohammad","year":"2015","unstructured":"Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR. Alemtuzumab as Remission induction therapy in Behcet Disease: a 20-year experience. J Rheumatol. 2015;42(10):1906\u201313. https:\/\/doi.org\/10.3899\/jrheum.141344.","journal-title":"J Rheumatol"},{"issue":"5","key":"3123_CR236","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10792-016-0370-9","volume":"37","author":"MD Willis","year":"2017","unstructured":"Willis MD, Pickersgill TP, Robertson NP, Lee RWJ, Dick AD, Carreno E. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. Int Ophthalmol. 2017;37(5):1229\u201333. https:\/\/doi.org\/10.1007\/s10792-016-0370-9.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"3123_CR237","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","volume":"28","author":"C Fabiani","year":"2020","unstructured":"Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Di Scala G, et al. The Presence of Uveitis is Associated with a sustained response to the interleukin (IL)-1 inhibitors Anakinra and Canakinumab in Behcet\u2019s Disease. Ocul Immunol Inflamm. 2020;28(2):298\u2013304. https:\/\/doi.org\/10.1080\/09273948.2018.1511810.","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"3123_CR238","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","volume":"37","author":"J Sota","year":"2018","unstructured":"Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37(8):2233\u201340. https:\/\/doi.org\/10.1007\/s10067-018-4119-x.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3123_CR239","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191\u20137. https:\/\/doi.org\/10.1007\/s10067-016-3506-4.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3123_CR240","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","volume":"25","author":"IM Tugal-Tutkun","year":"2017","unstructured":"Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, Lee SCMP, Ozdal P, Ozyazgan Y, et al. Safety and Efficacy of Gevokizumab in patients with Behcet\u2019s Disease Uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017;25(1):62\u201370. https:\/\/doi.org\/10.3109\/09273948.2015.1092558.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"3123_CR241","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","volume":"26","author":"I Tugal-Tutkun","year":"2018","unstructured":"Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gul A. Use of Gevokizumab in patients with Behcet\u2019s Disease Uveitis: An International, Randomized, Double-Masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023\u201333. https:\/\/doi.org\/10.1080\/09273948.2017.1421233.","journal-title":"Ocul Immunol Inflamm"},{"key":"3123_CR242","doi-asserted-by":"publisher","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","volume":"13","author":"DD Arnold","year":"2022","unstructured":"Arnold DD, Yalamanoglu A, Boyman O. Systematic review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-mediated disorders. Front Immunol. 2022;13:888392. https:\/\/doi.org\/10.3389\/fimmu.2022.888392.","journal-title":"Front Immunol"},{"key":"3123_CR243","doi-asserted-by":"publisher","first-page":"946048","DOI":"10.1155\/2012\/946048","volume":"2012","author":"A Ogata","year":"2012","unstructured":"Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol. 2012;2012:946048. https:\/\/doi.org\/10.1155\/2012\/946048.","journal-title":"Int J Rheumatol"},{"issue":"5","key":"3123_CR244","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","volume":"57","author":"B Atienza-Mateo","year":"2018","unstructured":"Atienza-Mateo B, Calvo-Rio V, Beltran E, Martinez-Costa L, Valls-Pascual E, Hernandez-Garfella M, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet\u2019s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856\u201364. https:\/\/doi.org\/10.1093\/rheumatology\/kex480.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3123_CR245","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","volume":"26","author":"H Eser Ozturk","year":"2018","unstructured":"Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the Treatment of Behcet Uveitis that failed Interferon Alpha and Anti-tumor Necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2018;26(7):1005\u201314. https:\/\/doi.org\/10.1080\/09273948.2017.1355471.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"3123_CR246","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","volume":"129","author":"M Leclercq","year":"2022","unstructured":"Leclercq M, Andrillon A, Maalouf G, Seve P, Bielefeld P, Gueudry J, et al. Anti-tumor Necrosis factor alpha versus Tocilizumab in the treatment of Refractory Uveitic Macular Edema: a Multicenter Study from the French Uveitis Network. Ophthalmology. 2022;129(5):520\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.013.","journal-title":"Ophthalmology"},{"issue":"Suppl 132","key":"3123_CR247","doi-asserted-by":"publisher","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","volume":"39","author":"B Atienza-Mateo","year":"2021","unstructured":"Atienza-Mateo B, Beltran E, Hernandez-Garfella M, Valls Pascual E, Martinez-Costa L, Atanes A, et al. Tocilizumab in Behcet\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes. Clin Exp Rheumatol. 2021;39(Suppl 132):37\u201342. https:\/\/doi.org\/10.55563\/clinexprheumatol\/9ipkcs.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"3123_CR248","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777\u201387. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.040.","journal-title":"Ophthalmology"},{"issue":"5","key":"3123_CR249","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","volume":"122","author":"E Letko","year":"2015","unstructured":"Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.033.","journal-title":"Ophthalmology"},{"issue":"5","key":"3123_CR250","doi-asserted-by":"publisher","first-page":"omz041","DOI":"10.1093\/omcr\/omz041","volume":"2019","author":"E Dincses","year":"2019","unstructured":"Dincses E, Yurttas B, Esatoglu SN, Melikoglu M, Hamuryudan V, Seyahi E. Secukinumab induced Behcet\u2019s syndrome: a report of two cases. Oxf Med Case Rep. 2019;2019(5):omz041. https:\/\/doi.org\/10.1093\/omcr\/omz041.","journal-title":"Oxf Med Case Rep"},{"issue":"4","key":"3123_CR251","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","volume":"72","author":"EM Baerveldt","year":"2013","unstructured":"Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP. Successful long-term triple disease control by ustekinumab in a patient with Behcet\u2019s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72(4):626\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202392.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3123_CR252","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","volume":"7","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, D\u2019Haens G, Panes J, Dignass A, Magro F, et al. Treat to target versus standard of care for patients with Crohn\u2019s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7(4):294\u2013306. https:\/\/doi.org\/10.1016\/S2468-1253(21)00474-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3123_CR253","doi-asserted-by":"publisher","unstructured":"Zou J, Lin CH, Wang Y, Shen Y, Guan JL. Correspondence on \u2018A pilot study of tofacitinib for refractory Behcet\u2019s syndrome\u2019. Ann Rheum Dis 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219810.","DOI":"10.1136\/annrheumdis-2020-219810"},{"key":"3123_CR254","doi-asserted-by":"publisher","unstructured":"Tao T, He D, Peng X, Huang Z, Su W. Successful Remission with Upadacitinib in Two Patients with Anti-TNF-Refractory Macular Edema Associated with Behcet\u2019s Uveitis. Ocul Immunol Inflamm 2023:1\u20134. https:\/\/doi.org\/10.1080\/09273948.2023.2263557.","DOI":"10.1080\/09273948.2023.2263557"},{"issue":"5","key":"3123_CR255","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1055\/a-1741-8104","volume":"239","author":"Y El-Shabrawi","year":"2022","unstructured":"El-Shabrawi Y, Rath T, Heiligenhaus A. Janus kinase inhibitors: next-generation treatment for Uveitis. Klin Monbl Augenheilkd. 2022;239(5):695\u2013701. https:\/\/doi.org\/10.1055\/a-1741-8104.","journal-title":"Klin Monbl Augenheilkd"},{"key":"3123_CR256","doi-asserted-by":"publisher","first-page":"111291","DOI":"10.1016\/j.biopha.2021.111291","volume":"136","author":"X Yin","year":"2021","unstructured":"Yin X, Qiu Y, Li Z, Guo L, Wei H, Liu B, et al. Longdan Xiegan Decoction alleviates experimental autoimmune uveitis in rats by inhibiting notch signaling pathway activation and Th17 cell differentiation. Biomed Pharmacother. 2021;136:111291. https:\/\/doi.org\/10.1016\/j.biopha.2021.111291.","journal-title":"Biomed Pharmacother"},{"key":"3123_CR257","doi-asserted-by":"publisher","first-page":"1215329","DOI":"10.3389\/fimmu.2023.1215329","volume":"14","author":"AG Gravina","year":"2023","unstructured":"Gravina AG, Pellegrino R, Palladino G, Coppola A, Brandimarte G, Tuccillo C, et al. Hericium erinaceus, in combination with natural flavonoid\/alkaloid and B(3)\/B(8) vitamins, can improve inflammatory burden in inflammatory bowel diseases tissue: an ex vivo study. Front Immunol. 2023;14:1215329. https:\/\/doi.org\/10.3389\/fimmu.2023.1215329.","journal-title":"Front Immunol"},{"issue":"3","key":"3123_CR258","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.4049\/jimmunol.0903853","volume":"185","author":"X Qin","year":"2010","unstructured":"Qin X, Guo BT, Wan B, Fang L, Lu L, Wu L, et al. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J Immunol. 2010;185(3):1855\u201363. https:\/\/doi.org\/10.4049\/jimmunol.0903853.","journal-title":"J Immunol"},{"issue":"4","key":"3123_CR259","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1167\/iovs.12-11217","volume":"54","author":"Y Yang","year":"2013","unstructured":"Yang Y, Qi J, Wang Q, Du L, Zhou Y, Yu H, et al. Berberine suppresses Th17 and dendritic cell responses. Invest Ophthalmol Vis Sci. 2013;54(4):2516\u201322. https:\/\/doi.org\/10.1167\/iovs.12-11217.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3123_CR260","doi-asserted-by":"publisher","first-page":"106270","DOI":"10.1016\/j.intimp.2020.106270","volume":"81","author":"Z Du","year":"2020","unstructured":"Du Z, Wang Q, Huang X, Yi S, Mei S, Yuan G, et al. Effect of berberine on spleen transcriptome and gut microbiota composition in experimental autoimmune uveitis. Int Immunopharmacol. 2020;81:106270. https:\/\/doi.org\/10.1016\/j.intimp.2020.106270.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3123_CR261","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3892\/mmr.2016.5980","volume":"15","author":"Y Yang","year":"2017","unstructured":"Yang Y, Wang Q, Xie M, Liu P, Qi X, Liu X, et al. Berberine exerts an anti-inflammatory role in ocular Behcet\u2019s disease. Mol Med Rep. 2017;15(1):97\u2013102. https:\/\/doi.org\/10.3892\/mmr.2016.5980.","journal-title":"Mol Med Rep"},{"key":"3123_CR262","doi-asserted-by":"publisher","unstructured":"Wang C, Zhou W, Su G, Hu J, Yang P. Progranulin suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by inhibiting Th1\/Th17 cells and promoting Treg Cells and M2 macrophages. Neurol Neuroimmunol Neuroinflamm. 2022;9(2). https:\/\/doi.org\/10.1212\/NXI.0000000000001133.","DOI":"10.1212\/NXI.0000000000001133"},{"issue":"2","key":"3123_CR263","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1161\/CIRCRESAHA.120.317789","volume":"128","author":"G Emmi","year":"2021","unstructured":"Emmi G, Bettiol A, Niccolai E, Ramazzotti M, Amedei A, Pagliai G, et al. Butyrate-Rich diets improve redox status and fibrin lysis in Behcet\u2019s syndrome. Circ Res. 2021;128(2):278\u201380. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317789.","journal-title":"Circ Res"},{"issue":"4","key":"3123_CR264","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijheh.2011.04.001","volume":"214","author":"M Pehlivan","year":"2011","unstructured":"Pehlivan M, Kurtuncu M, Tuzun E, Shugaiv E, Mutlu M, Eraksoy M, et al. The comparison of socio-economic conditions and personal hygiene habits of neuro-Behcet\u2019s disease and multiple sclerosis patients. Int J Hyg Environ Health. 2011;214(4):335\u20137. https:\/\/doi.org\/10.1016\/j.ijheh.2011.04.001.","journal-title":"Int J Hyg Environ Health"},{"issue":"5","key":"3123_CR265","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.0954-6820.1984.tb05044.x","volume":"216","author":"H Larsson","year":"1984","unstructured":"Larsson H, Bengtsson-Stigmar E. Behcet\u2019s disease and close contact with pigs. Acta Med Scand. 1984;216(5):541\u20133. https:\/\/doi.org\/10.1111\/j.0954-6820.1984.tb05044.x.","journal-title":"Acta Med Scand"},{"issue":"SI\u20132","key":"3123_CR266","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3906\/sag-2003-147","volume":"50","author":"G Mumcu","year":"2020","unstructured":"Mumcu G, Alibaz Oner F, Ergun T, Direskeneli RH. Decreasing incidence and severity of Behcet\u2019s disease: a changing trend in epidemiological spectrum possibly associated with oral health. Turk J Med Sci. 2020;50(SI\u20132):1587\u201390. https:\/\/doi.org\/10.3906\/sag-2003-147.","journal-title":"Turk J Med Sci"},{"issue":"4 Suppl 60","key":"3123_CR267","first-page":"S86","volume":"28","author":"H Direskeneli","year":"2010","unstructured":"Direskeneli H, Mumcu G. A possible decline in the incidence and severity of Behcet\u2019s disease: implications for an infectious etiology and oral health. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S86\u201390.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"3123_CR268","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/rheumatology\/keh236","volume":"43","author":"G Mumcu","year":"2004","unstructured":"Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, et al. Oral health is impaired in Behcet\u2019s disease and is associated with disease severity. Rheumatology (Oxford). 2004;43(8):1028\u201333. https:\/\/doi.org\/10.1093\/rheumatology\/keh236.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3123_CR269","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/rheumatology\/ker345","volume":"51","author":"F Chen","year":"2012","unstructured":"Chen F, Hou S, Jiang Z, Chen Y, Kijlstra A, Rosenbaum JT, et al. CD40 gene polymorphisms confer risk of Behcet\u2019s disease but not of Vogt-Koyanagi-Harada syndrome in a Han Chinese population. Rheumatology (Oxford). 2012;51(1):47\u201351. https:\/\/doi.org\/10.1093\/rheumatology\/ker345.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3123_CR270","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00439-012-1200-4","volume":"131","author":"S Hou","year":"2012","unstructured":"Hou S, Xiao X, Li F, Jiang Z, Kijlstra A, Yang P. Two-stage association study in Chinese Han identifies two independent associations in CCR1\/CCR3 locus as candidate for Behcet\u2019s disease susceptibility. Hum Genet. 2012;131(12):1841\u201350. https:\/\/doi.org\/10.1007\/s00439-012-1200-4.","journal-title":"Hum Genet"},{"issue":"4","key":"3123_CR271","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3109\/02713683.2011.635398","volume":"37","author":"Y Chen","year":"2012","unstructured":"Chen Y, Yang P, Li F, Hou S, Jiang Z, Shu Q, et al. Association analysis of TGFBR3 gene with Vogt-Koyanagi-Harada disease and Behcet\u2019s disease in the Chinese Han population. Curr Eye Res. 2012;37(4):312\u20137. https:\/\/doi.org\/10.3109\/02713683.2011.635398.","journal-title":"Curr Eye Res"},{"issue":"1","key":"3123_CR272","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clim.2008.06.006","volume":"129","author":"S Hou","year":"2008","unstructured":"Hou S, Yang P, Du L, Zhou H, Lin X, Liu X, et al. SUMO4 gene polymorphisms in Chinese Han patients with Behcet\u2019s disease. Clin Immunol. 2008;129(1):170\u20135. https:\/\/doi.org\/10.1016\/j.clim.2008.06.006.","journal-title":"Clin Immunol"},{"issue":"13","key":"3123_CR273","doi-asserted-by":"publisher","first-page":"8384","DOI":"10.1167\/iovs.13-12878","volume":"54","author":"J Fang","year":"2013","unstructured":"Fang J, Hu R, Hou S, Ye Z, Xiang Q, Qi J, et al. Association of TLR2 gene polymorphisms with ocular Behcet\u2019s disease in a Chinese Han population. Invest Ophthalmol Vis Sci. 2013;54(13):8384\u201392. https:\/\/doi.org\/10.1167\/iovs.13-12878.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3123_CR274","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/ar3789","volume":"14","author":"S Hou","year":"2012","unstructured":"Hou S, Shu Q, Jiang Z, Chen Y, Li F, Chen F, et al. Replication study confirms the association between UBAC2 and Behcet\u2019s disease in two independent Chinese sets of patients and controls. Arthritis Res Ther. 2012;14(2):R70. https:\/\/doi.org\/10.1186\/ar3789.","journal-title":"Arthritis Res Ther"},{"key":"3123_CR275","doi-asserted-by":"publisher","first-page":"724900","DOI":"10.3389\/fimmu.2021.724900","volume":"12","author":"T Novak","year":"2021","unstructured":"Novak T, Hamedi M, Bergmeier LA, Fortune F, Hagi-Pavli E. Saliva and serum cytokine profiles during oral Ulceration in Behcet\u2019s Disease. Front Immunol. 2021;12:724900. https:\/\/doi.org\/10.3389\/fimmu.2021.724900.","journal-title":"Front Immunol"},{"issue":"3 Suppl 77","key":"3123_CR276","first-page":"32","volume":"31","author":"SY Na","year":"2013","unstructured":"Na SY, Park MJ, Park S, Lee ES. Up-regulation of Th17 and related cytokines in Behcet\u2019s disease corresponding to disease activity. Clin Exp Rheumatol. 2013;31(3 Suppl 77):32\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3123_CR277","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","volume":"19","author":"JMG Ruiz de Morales","year":"2020","unstructured":"Ruiz de Morales JMG, Puig L, Dauden E, Canete JD, Pablos JL, Martin AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. https:\/\/doi.org\/10.1016\/j.autrev.2019.102429.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"3123_CR278","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1167\/iovs.07-1390","volume":"49","author":"W Chi","year":"2008","unstructured":"Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49(7):3058\u201364. https:\/\/doi.org\/10.1167\/iovs.07-1390.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03123-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-024-03123-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03123-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:06:18Z","timestamp":1716390378000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-024-03123-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":278,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3123"],"URL":"https:\/\/doi.org\/10.1186\/s12974-024-03123-6","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Take-home messages"}}],"article-number":"133"}}